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Abstract 
Angiotensin converting enzyme (ACE) (EC 3.4.15.1) plays a vital role in 
maintaining blood pressure and cardiovascular health as part of the renin-angiotensin-
aldosterone system (RAAS) (Schmieder et al., 2007). ACE functions by cleaving 
angiotensin I (Ang I) to produce angiotensin II (Ang II), an active vasoconstrictor and 
important part of RAAS regulation, and also by inactivating brandykinin, a vasodilator 
(Harrison and Acharya, 2014). A major polymorphism of ACE occurs in intron 16, where 
there can be an Alu sequence inserted, resulting in two different alleles: one containing 
the insertion (I- insertion) and one without it(D- deletion) (Harrison and Acharya, 2014).  
The D allele of ACE has been shown to produce more mRNA than the I allele 
(Suehiro et al., 2004), while the I/D polymorphism has been linked with nearly half the 
variance in serum ACE levels between individuals (Rigat et al., 1990). The brain has 
independent ACE expression, and the I allele has been linked with a 70% increase in 
ACE promoter transcription in neuro (Wu enst al., 2013). This apparent difference in 
ACE expression between the brain and the periphery within the same genotype, and the 
differences in expression between genotypes, likely have an effect on the cardiovascular 
and musculoskeletal systems where ACE activity is involved. This study attempted to 
examine these effects through the differential significant correlations of physical 
performance and strength measurements seen between the genotype groups. 
iii 
 
The study involved 88 participants who underwent physical assessments and ACE 
genotype analysis. The results showed distinct differences in significant correlations 
between the genotype groups. Balance measure were significantly correlated with 
strength in the I/I and I/D groups, but not in the D/D group. Stepping also had significant 
correlations with strength in the I/I and I/D groups not seen in D/D, but significant 
correlations between gait and strength were seen in I/D and D/D but not I/I. Additionally, 
the study found a lack of significant correlations between tests like the Sit to Stand (STS) 
test and strength in the I/I group, and few significant correlations with strength in the 
D/D, suggesting that the process of administering tests to evaluate strength should 
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Angiotensin converting enzyme [(ACE) (EC 3.4.15.1)} is part of the renin-
angiotensin-aldosterone system (RAAS), responsible for regulating both the renal and 
cardiovascular systems (Schmieder et al., 2007). ACE is a dipeptidyl carboxypeptidase, 
dependent on zinc to remove the C-terminal dipeptide from its substrates and has two 
homologous domains, the N-domain and the C-domain (Harrison and Acharya, 2014). 
The domains each have an active site than can often act on the same substrates, but have 
different chloride ion concentration needs to be effective and can have different activity 
levels in different locations; the domains share a 60% identity homology, likely due to a 
gene duplication event which expanded its original function (Masuyer et al., 2014).  
Angiotensin I (Ang I) is cleaved by ACE and produces angiotensin II (Ang II), a 
potent vasoconstrictor which stimulates Angiotensin II type 1 and type 2 receptors (AT1, 
AT2); ACE also inactivates bradykinin, a vasodialator, and so acts to raise blood pressure 
with both activities (Harrison and Acharya, 2014). ACE acts on other substrates as well, 
including some also involved in RAAS (Schmieder et al., 2007), which affects various 
tissues around the body, including skeletal muscles (Underwood and Adler, 2013). ACE 
has been shown to be vital for proper fetal development; without membrane bound ACE, 
kidneys do not develop properly, leading to perinatal death (Michaud et al., 2014). An 
ACE isoform is also expressed in the testis and is needed for proper male fertility; 
without its dicarboxypeptidase activity, sperm look and move normally, but are not able 





The ACE gene has a polymorphism in intron 16, where an Alu sequence may be 
inserted (I) or may be deleted (D), giving rise to three possible genotypes: I/I, I/D, and 
D/D (Harrison and Acharya, 2014). This polymorphism and the resulting genotypes have 
been linked to various conditions through hundreds of different studies and have been 
strongly associated with hypertension, with renal production of Ang II being shown to be 
necessary for experimental hypertension to develop (Giani et al., 2015) and the absence 
of intrarenal ACE protecting against the development of hypertension (Gonzalez-
Villalobos et al., 2013). While ACE inhibitors protect against various other 
cardiovascular troubles, such as coronary heart disease and myocardial infarction (Fagyas 
et al., 2014), no significant link has been found between these diseases and the ACE 
genotype (Kitsios et al., 2009). The D allele has been found to cause higher levels of 
mRNA to be produced (Suehiro et al., 2004), and ACE was also more active, producing 
more Ang II in D/D (Hamdi and Castellon, 2004). While the I/D polymorphism was 
correlated with and has been found accountable for up to half of ACE serum levels (Rigat 
et al., 1990), the specific mechanism that accounts for this difference has yet to be 
elucidated. The D/D genotype has been linked to insulin resistance in type II diabetes 
(Underwood and Adler, 2013) and a susceptibility to schizophrenia in women (Mazaheri 
et al., 2015), but has also been shown to be protective against Alzheimer’s development 
because ACE acts to degrade amyloid β-proteins (Hemming et al., 2005; Kehoe, 2009). 
The D/D and I/D genotypes are both linked to diabetic peripheral neuropathy (Xu et al., 
2015), while I/D is linked with rejection of kidney transplants (Huang et al., 2015). The 





starvation (Hamdi and Castellon, 2004), manifesting itself as protection against age-
related macular degeneration (Hamdi et al., 2002).  
Additionally, ACE genotypes have been linked to extreme athleticism, but the 
results are sometimes conflicting: in elite Israeli athletes, the D allele and D/D genotype 
were associated with endurance athletes (Amir et al., 2007) while the D allele was linked 
to elite short distance swimming in Portuguese Olympic swimmers (Costa et al., 2009). 
The D allele was associated with endurance performance in elite Iranian athletes 
(Shahmoradi et al., 2014), but in Tunisian athletes, the I allele was associated with 
endurance and the D allele with power performance (Znazen et al., 2015). The I allele has 
also been linked with increased heat tolerance during exercise for Caucasian men who 
were not elite athletes (Heled et al., 2004). These contradictory results hint at the 
complicated nature of RAAS, ACE, and how they interact with the body in a variety of 
ways. 
Alu Sequences 
Human genes are composed of exons and introns that are transcribed to pre-mRNA, 
before the introns are removed and exons are spliced together. Exons can be spliced, or 
joined, together in various orders to make different isoforms of the proteins, increasing 
the possible number of proteins without adding size to the genome (Ram et al., 2008). Alu 
sequences are primate-specific repetitive elements that belong to the SINE (short 
interspersed elements) family of retrotransposons and are found throughout the genome 
with 1.07 million copies, 10% of the total genome mass. (Gal-Mark et al., 2008). Alu 
sequences arose from a fusion of the 7SL RNA gene, which produced fossil Alu 





modern Alu structure: related right- and left-arm monomers with an A-rich linker, but 
with distinct difference, such as a 31 nt insert in the right arm (Hasler and Strub, 2006). 
Importantly, Alu sequences maintain elements from the ancestral 7SL RNA gene- internal 
A and B boxes of the RNA polymerase III promoter that are weak but functional (Fig. 1). 
These elements cannot drive efficient Alu transcription alone due to significant 
divergence from consensus, but can be influenced by flanking sequences to promote 
transcription (Hasler and Strub, 2006). Alu RNA itself is thought to play some role in cell 
metabolism, as its normally low cytosol levels were increased during various stresses and 
decrease after recovery. Further studies have indicated Alu RNA may have a specific role 
in the regulation of protein translation (Hasler and Strub, 2006).  
 
Figure 1      (Hasler and Strub, 2006) 
Architecture of Alu elements. Alu elements are about 300 nt long; they have a dimeric structure 
composed of two related but not equivalent monomers (left and right arms). The right arm 
contains a 31 nt insertion as compared to the left arm. Left and right arms are separated by an A-
rich region (Mid A-stretch) and followed by a short poly(A) tail (Terminal A-stretch). The left arm 





Alu are short sequences (287 nt) that are composed of a right arm and left arm, 
which are very similar but with some differences: The left arm contains an internal 
promoter for RNA polymerase III, while the right arm has a unique 31 bp insert, and they 
are joined by an A-rich linker, followed by a poly(A) tail (Fig. 2) (Gal-Mark et al., 2008). 
Alu sequences can be inserted in either the antisense or sense orientation, with the 
antisense most commonly leading to exonization of the right arm of Alu and nearby 
sequences (Gal-Mark et al., 2008). Alu exonization plays no small role in human lives, as 
it accounts for more than 5% of the alternatively spliced internal exons in the genome 
(Ram et al., 2008). The Alu in intron 16 of ACE makes it a good candidate to examine for 
alternative splicing. Alu inserts on their own are not enough to cause exonization, but do 
so with the help of a few key mutations. The ACE Alu insert belongs to the young 
subfamily Ya5; the older subfamilies AluS/J can undergo exonization with just a single 
mutation. However, a few more were necessary to cause the ACE Alu to alternatively 
splice, which was also promoted by a specific subset of SR proteins (Lei et al., 2005). 
Splicing requires specific sequence features that can interact with the spliceosome 
complex, composed of 5 small nuclear ribonucleoproteins and over 200 proteins (Gal-
Mark et al., 2008). The spliceosome recognizes the polypyrimidine tract (PPT), the 5’ 
and 3’ splice sites (5’ss and 3’ss) and the branch point sequence (BPS), with cis-acting 
intronic and exonic splicing regulatory elements (ISRs/ESRs) also needed to facilitate the 
process (Gal-Mark et al., 2008). With the 5’ss and 3’ss of the ACE Alu mutated and 
optimized, exonization leading to alternative splicing can be induced; this can also be 
done with a single point mutation (G282C) and an overexpression of SR proteins, which 





alternative splicing have been identified, their occurrence has not been studied in 
populations, and any resulting alternative splicing has not been characterized. 
Interestingly, deletion of the left arm of the Alu sequence changes the exonization of the 
right arm from alternatively spliced to constitutively spliced, which would be detrimental 




Figure 2        (Gal-Mark et al., 2008) 
Alignment of the right and left arm of Alu J consensus sequence (gi551536) in its antisense 
orientation (relative to the mRNA) using the MAVID alignment server. The PPT of the right arm 
was extended to 19 nt as, on average, the PPT length in exonized Alus is 19 bases ±3 and is 
marked by horizontal brackets. The major 3′ss and 5′ss that are selected by Alu exons are 
indicated by arrows. Identical sequences are highlighted in gray. The 31-nt sequence that is 
present only in the right arm is indicated in a box. 
 
ACE Expression and Isoforms 
Intron 16 may have effects on transcription as well: an 18 bp sequence has been 
identified that is highly conserved across species and was a potential binding site 
transcription factors (TFs) HFH-1, Oct-1, and HNF-3β, although specific interactions 





allele was found to have a positive effect on the ACE promoter, increasing its 
transcriptional activity in neurons by 70% (Wu et al., 2013). However, the promoter and 
the Alu sequences were not in the same orientation as in the ACE gene, so the results 
should be confirmed by further experiments. Additionally, the brain has a separate ACE 
expression system (Wu et al., 2013), and so these results may not apply to the ACE 
expressed in the rest of the body. Other transcriptional regulation has been proposed and 
ruled out, such as a transcriptional silencer that is missing in the D allele (Rosatto et al., 
1999), but the methodology in this and most other studies have some key shortcomings. 
Often fragments of intron 16 I and D alleles or the Alu will be cloned into vectors with 
reporter genes, but this is missing any interactions caused by the rest of the mRNA and 
its secondary structure. Animal models that produce ACE are very helpful for studying 
other aspects, but the Alu insert in intron 16 is only found in humans, so all other animals 
are by default D/D (Hamdi and Castellon, 2004) and thus can’t be used to study the I 
allele effects on splicing. When human ACE (hACE) is used in animal model, it is 
usually the coding sequence for the protein with the introns already removed; the 
otherwise over 20,000 bp sequence would be far too large to use with plasmids, and 
would likely need an artificial chromosome. In the study that looked at how to induce 
alternative splicing of the ACE Alu sequence, only intron 16 or its fragments were cloned 
into minigenes (Lei at al., 2005), which has the advantage of looking at the complete 
intron 16, but again loses out on any interactions from the rest of the pre-mRNA that 
might affect splicing. The I allele has been shown to increase ACE promoter activity by 
70% in neuron cells, however this was done using constructed plasmids, not the gene in 





There are already two recognized isoforms of ACE, somatic ACE (sACE- 170 
kDa) and testis ACE (tACE- 110 kDa), only produced in the testis after puberty and 
comprised of the C-domain of sACE (Harrison and Acharya, 2014). The ACE gene has 
26 exons and 25 introns, with sACE generated by splicing exons 1-12 and 14-26 together, 
while tACE is made by splicing exons 13-26 together (Masuyer et al., 2014). Along with 
the N- and C- domains, ACE has a juxtamembrane domain, a transmembrane domain 
(hydrophobic), and a cytoplasmic region. (Masuyer et al., 2014). Both forms of ACE 
exist as membrane bound proteins, exposed on the cellular membrane surface as well as 
on internal membranes (Wang et al., 2015); both can be cleaved by serine proteases 
called ACE sheddases to become soluble and enter serum (Aragao et al., 2015). This 
cleavage can occur at different residues, giving different isoforms that can be detected in 
the blood and urine. Other mutations in the ACE gene have also been found to affect 
shedding and lead to higher ACE plasma levels, and should possibly be considered in 
future studies looking at the effects of different ACE genotypes (Ehlers et al., 2012). 
The low molecular weight (LMW) isoform of soluble ACE is around 65 kDa, and 
results from the N-domain being cleaved at Ser482 in rats and mice (Fig. 5) (Aragao et al., 
2015). The complete sACE comprised of both domains can also be released by cleaving 
at Arg1137 (Fig. 3), producing soluble ACE with both the N- and the C-domains (Beldent 
et al., 1995). ACE undergoes other modifications as well and is extensively glycosylated 
to ensure correct folding, with 8 of the 10 potential N-glycosylation sites in the N-domain 
being glycosylated; the C-domain has 7 potential sites, with 3 of them always and 3 
others partially glycosylated (Masuyer et al., 2014). If one of those sites was affected by 





without full activity. However, the extensive glycosylation can also make it hard to 
predict the MW of soluble sACE (150-190 kDa) and other isoforms (Wang et al., 2015). 
Both of these isoforms, the 65 kDa LMW and 190 kDa sACE, have been isolated in the 
urine of humans and are associated with normotensive patients, while another 90 kDa 
form (Fig. 3) has also been found in the urine of patients that have history of 
hypertension for either themselves or family (Masuyer et al., 2015). This 90 kDa form of 
the N-domain of ACE is cleaved at a different residue than the 65 kDa form, Pro629 
(Aragao et al., 2015), and is used as a biomarker for hypertension (Maluf-Meiken et al., 
2012). Because of this, hypertension would seem to be linked to the D allele.  
 
 
Figure 3        (Aragao et al., 2015) 
Sequence alignment of rat (UniProtKB/Swiss-Prot: P47820.1) and mouse (UniProtKB/Swiss-Prot: 
P09470.3) sACE. The C-terminal alignment of 65 kDa rat nACE ended at Ser482. The same 
analysis for 90 kDa rat nACE showed that the enzyme sequence ended at Pro629. 
 
 
 ACE plays a multitude of roles throughout the body, interacting with a variety of 
different systems. ACE is linked with many diseases and conditions, but the strongest is 
perhaps with hypertension. However, genotype for ACE did not accurately predict 





difficulty in effectively planning treatments. Additionally, ACE is involved with many 
processes in the body, long-term treatment could cause other problems, such as inhibiting 
ACE and removing protection from Alzheimer’s that ACE provides by degrading 
amyloid β-proteins (Hemming and Selkoe, 2005). The associations between ACE 
genotype and physical condition/ability could potentially lead to tailor-made physical 
therapies for patients based on how their cardiovascular system responds to exercise and 
stress based on their ACE genotype.  If a link is found, this could also possibly lead to 
custom physical therapies for the elderly that they will get the most benefit from, done in 
either a preventative way to retain strength and mobility, or as part of recovery from 
conditions such as heart attack or stroke. With the broad range of ACE involvement with 
the cardiovascular system, links to disease like hypertension, Alzheimer’s, and 
schizophrenia, and the vital role ACE plays in male fertility and proper fetal 
development, knowledge of the effects of the Alu I/D polymorphism on protein 
expression and activity, and how this affects the whole body throughout life, will be 






Methods and Materials 
Subjects for the study were selected from senior communities in and around Flint, 
MI. A total of 88 subjects were tested, selected based on the following criteria. 
Inclusionary Criteria  
Subjects were eligible be included in this project if they meet the following criteria: 
1. Age 60 years or more. 
2. Able to stand for 10 minutes without human assistance. 
3. Able to walk without human assistance with or without an assistive device. 
Exclusionary Criteria 
Subjects were excluded from this study under the following conditions: 
1. Cognitive impairment (ie not alert or oriented and are therefore unable to 
understand the instructions being provided to them). 
2. History of neurological disease e.g. stroke, Parkinson’s disease, or other 
neurological disease. 
3. Self-report of any of the following: cardiopulmonary symptoms such as shortness 
of breath/fatigue or chest pain with minimal exertion, currently being treated for 
cancer or that they are in the terminal stages of cancer, currently being treated for 
an infection, fracture in the past 6 months that would interfere with testing, pain 
that requires medication and that would interfere with testing. 






Once selected, saliva samples were collected from subjects using the Oragene DNA 
OG 500 kit ( DNA Genotek, Ottawa, ON, Canada) and stored for later testing at room 
temperature. Subjects then underwent a series of physical performance tests as follows. 
a) Walk a distance of up to 32.5 feet (10 meters) at usual pace and at fast pace to assess 
walking speeds (Usual Gait Speed- UGS; and Fast Gait Speed- FGS) 
b) Push or pull legs against resistance to record muscle strength in pounds/kilograms of 
hip flexor (Hip Flex), knee extensor (Knee Extension), and ankle dorsi-flexor muscle 
groups (Ankle Flex)  
c) Squeeze a hand-device to record grip strength (Grip Strength)  
d) Go from sit to stand and to sit again rapidly 5 times to determine leg function in terms 
of speed (Sit to Stand- STS) 
e) Step as rapidly as possible from one foot pad to another to determine response time 
(Lower Extremity response time- LE) 
f) Step rapidly forward and back again a distance of 18” with one leg up to 30 times 
(Rapid Step Test- RST) 
g) Step as far as possible with preferred leg to determine leg function in terms of distance 
(Max Step Length- MSL)  
h) Perform balance tests- standing on one leg (Single Leg Stand Time- SLST) and 
stepping in various directions within 4 squares on the floor (Four-Square Step Test- 
FSST)    
 
 DNA was extracted from saliva sample using the PrepIT L2P kit (DNA Genotek, 
Ottawa, ON, Canada) and provided instructions. Once extracted, the DNA underwent 
PCR amplification. The primers used flanked the polymorphic DNA segment in intron 16 
of the ACE gene: forward primer- 5’ CTG GAG AGC CAC TCC CAT CCT TTC T 3’; 
reverse primer- 5’ GAC GTG GCC ATC ACA TTC GTC AGA T 3’. The band for the I 
allele was 478 bp, and the band for the D allele was 191 bp. However, the I allele band 





performed on samples that showed only a D band (Fig. 4). The same reverse primer was 
used, but a different forward primer that base-pair matches to the Alu insert itself was 
used, so only I alleles were amplified, resulting in a band of about 450 bp; confirm 
forward primer- 5’ TTT GAG ACG GAG TCT CGC TC 3’. The PCR reaction results 
were visualized in gels made with 1.5% agarose in 0.5 X TBE. 
 
Figure 4 
Example of gel results for the ACE I/D polymorphism genotypes. Note that the confirm PCR is 
necessary to obtain the correct genotype for sample 32. M= Molecular ladder marker; D and I 




A total of 88 individuals participated in the study. The I/D genotype group 
contained 48 participants with a mean age of 71.1 years old +/- 6.8 years, and was 79% 
female. The 23 members of the D/D genotype group were 78% female with a mean age 
of 72.9 years old +/- 10.5 years. The I/I group’s 17 members had a mean age of 72.7 
years old +/- 7.6 years and were 76% female. The allele frequencies were in Hardy-
Weinberg equilibrium. Data was statistically analyzed via SPSS (IBM v. 24). Kruskal-





Bivariate correlation analysis to compute Spearman’s coefficient was performed 
to determine correlation differences between the variables in the different genotype 
groups.  The physical performance tests used for correlation were Lower Extremity 
response time- LE (best score), Sit to Stand- STS (best score), Rapid Step Test- RST 
(best score), Max Step Length- MSL (adjusted for height), Single Leg Stand Time- SLST 
(best score), Four-Square Step Test- FSST (best score), Usual Gait Speed- UGS (best 
score), and Fast Gait Speed- FGS (best score). The best score was used as all participants 
did not complete multiple trials of each test. The strength tests- Hip, Knee, Ankle, and 
Grip, were adjusted for weight, and were also combined for a Composite Strength score, 
all of which were analyzed for correlations. Correlations were found between all physical 
performance and strength measures in the whole sample (Table 1), but the relationships 




For the I/D genotype group (Table 2), STS was found to have significant 
correlations with all the other physical measures mentioned. There was a fair negative 
relationship between STS and SLST (r= -0.330, p=0.023), Knee Extension (r= -0.472, r= 
0.001), Ankle Flex (r= -0.431, p= 0.002), and Grip Strength (r= -0.443, p= 0.002). There 
were moderate negative relationships between STS and MSL (r= -0.599, p= 9.0 x 10-6), 
Hip Flex (r= -0.592, p= 1.2 x 10-5), Composite Strength (r= -0.560, p= 4.2 x 10-5), UGS 





positive relationships with LE response time (r= 0.500, p= 3.47 x 10-4) and FSST (r= 
0.623, p= 3.0 x 10-6) and a good positive relationship with RST (r=0.718, p= 1.98 x 10-8).  
For the D/D genotype group (Table 3), STS had moderate negative relationships 
with Hip Flex (r= -0.567, p= 0.006), Grip Strength (r= -0.644, p= 0.001), UGS (r=           
-0.584, p= 0.004) and FGS (r= -0.600, p= 0.003), as well as a fair positive relationship 
with RST (r= 0.430, p= 0.046) and a moderate positive relationship with LE (r= 0.516, 
p= 0.014).  
In the I/I genotype group (Table 4), STS only had one significant correlation, a 
moderate negative relationship with UGS (r= -0.539, p=0.026). 
LE Response Time 
For the D/D genotype group, LE response time had significant correlations with 
all the physical measures mentioned, as well as a fair positive relationship with being a 
recurrent faller (r= 0.467, p= 0.025), a relationship not seen in other genotype groups. In 
fact, in those possessing the D allele (Table 5), LE response time has fair positive 
relationships with being a recurrent faller (r= 0.236, p= 0.047) and the number of falls in 
the last 12 months (r= 0.249, p= 0.036). This did not occur with the I allele (Table 6).  
For the physical measures in the D/D group, LE response time had fair negative 
relationships with MSL (r= -0.435, p= 0.038), Knee Extension (r= -0.493, p= 0.017), 
Ankle Flex (r= -0.419, p= 0.047), and Composite Strength (r= -0.482, p= 0.020). There 
were moderate negative relationships with SLST (r= -0.569, p= 0.005), Hip Flex (r=        
-0.541, p= 0.008), and UGS (r= -0.567, p= 0.005), as well as good negative relationships 





were moderate positive relationships with STS (r= 0.516, p= 0.014), RST (r= 0.645, p= 
0.001), and FSST (r= 0.516, p= 0.014).  
For the I/D genotype group, significant correlations were found between LE 
response time and all the physical measures except Ankle Flex. Fair negative 
relationships occurred with SLST (r= -0.494, p= 3.58 x 10-4), Hip Flex (r= -0.384, p= 
0.007), Knee Extension (r= -0.344, p= 0.017), and Composite (r= -0.334, p= 0.020) and 
Grip Strength (r= -0.457, p= 0.001). Moderate negative relationships were found with 
MSL (r= -0.622, p= 2.0 x 10-6), UGS (r= -0.525, p= 1.30 x 10-4), and FGS (r= -0.615, p= 
3.0 x 10-6). A fair positive relationship was found with FSST (r= 0.479, p= 0.001), a 
moderate positive relationship with STS (r= 0.500, p= 3.47 x 10-4), and a good positive 
relationship with RST (r= 0.752, p= 1.14 x 10-9).  
For the I/I genotype group, LE response time had moderate negative relationships 
with Hip Flex (r= -0.574, p= 0.016), Knee Extension (r= -0.529, p= 0.029), Ankle Flex 
(r= -0.583, p= 0.014), Composite Strength (r= -0.642, p= 0.005), and Grip Strength (r=    
-0.525, p= 0.031), and a moderate positive relationship with RST (r= 0.547, p= 0.023).  
RST 
For the I/D and D/D genotype groups, RST had significant correlations with all 
other physical performance and strength measures. In the D/D genotype group, RST had 
fair negative relationships with Hip Flex (r= -0.484, p= 0.022), Ankle Flex (r= -0.440, p= 
0.041), and Composite Strength (r= -0.495, p= 0.019); moderate negative relationships 
with MSL (r= -0.508, p= 0.016), SLST (r= -0.523, p= 0.013), Knee Extension (r= -0.531, 





UGS (r = -0.692, p= 3.55 x 10-4) and FGS (r= -0.775, p= 2.3 x 10-5). RST had a fair 
positive relationship with STS (r= 0.430, p= 0.046), a moderate positive relationship with 
LE response time (r= 0.645, p= 0.001), and a good positive relationship with FSST (r= 
0.730, p= 1.16 x 10-4).  
For the I/D group, RST had fair negative relationships with Hip Flex (r= -0.409, 
p= 0.004), Knee Extension (r= -0.468, p= 0.001), Ankle Flex (r= -0.438, p= 0.002), 
Composite Strength (r= -0.492, p= 4.41 x 10-4), and Grip Strength (r= -0.472, p= 0.001); 
moderate negative relationships with SLST (r= -0.552, p= 5.8 x 10-5) and UGS (r= -
0.640, p= 1.0 x 10-6); and good negative relationships with MSL (r= -0.759, p= 6.47 x  
10-10) and FGS (r= -0.703, p= 3.59 x 10-8). RST had good positive relationships with LE 
response time (r= 0.752, p= 1.14 x 10-9), STS (r= 0.718, p= 1.98 x 10-8), and FSST (r= 
0.704, p= 3.47 x 10-8); RST also had fair positive correlations with BMI (r= 0.432, p= 
0.002) and the number of falls in the past 12 months (r= 0.294, p= 0.045) in the I/D 
group, not seen in other genotypes. 
 The I/I genotype group had significant correlations between RST and all physical 
performance and strength measures except STS, as well as a strong positive relationship 
with fear of falling (FOF) (r= 0.738, p= 0.001), but not with actual falls occurring. In the 
I/I group, RST had moderate negative relationships with SLST (r= -0.678, p= 0.003), Hip 
Flex (r= -0.657, p= 0.004), Knee Extension (r= -0.566, p= 0.018), Ankle Flex (r= -0.603, 
p= 0.010), Composite Strength (r= -0.674, p= 0.003), and Grip Strength (r= -0.512, p= 
0.036); a good negative relationship with MSL (r= -0.757, p= 4.30 x 10-4); and excellent 





10-7). RST also had a moderate positive relationship with LE response time (r= 0.547, p= 
0.023) and a good positive relationship with FSST (r= 0.775, p= 2.62 x 10-4). 
MSL 
The I/D and I/I groups both had significant correlations between MSL and nearly 
all other measures, while D/D had few MSL correlations. For I/D, significant correlations 
were found with all strength and physical activity measures. Moderate negative 
relationships were found with LE response time (r= -0.622, p= 2.0 x 10-6) and STS (r=     
-0.599, p= 9.0 x 10-6); good negative relationships with RST (r= -0.759, p= 6.47 x 10-10) 
and FSST (r= -0.706, p= 2.14 x 10-8); fair positive relationships with Hip Flex (r= 0.455, 
p= 0.001) and Grip Strength (r= 0.463, p= 0.001); moderate positive relationships with 
SLST (r= 0.609, p= 4.0 x 10-6), Knee Extension (r= 0.503, p= 2.71 x 10-4), Ankle Flex 
(r= 0.499, p= 3.04 x 10-3), Composite Strength (r= 0.521, p= 1.49 x 10-4), and UGS (r= 
0.601, p= 6.0 x 10-6); and a good positive relationship with FGS (r= 0.732, p= 3.49 x    
10-9).  
The I/I group had significant correlations between MSL and all the same 
measures except LE response time and STS. Good negative relationships were observed 
with RST (r= -0.757, p= 4.30 x 10-4) and FSST (r= -0.846, p= 1.9 x 10-5); a fair positive 
relationship with Ankle Flex (r= 0.485, p= 0.048); moderate positive relationships with 
Hip Flex (r= 0.618, p= 0.008), Knee Extension (r= 0.498, p= 0.042), Composite Strength 
(r= 0.569, p= 0.017), Grip Strength (r= 0.510, p= 0.037), and UGS (r= 0.667, p= 0.003); 
and good positive relationships with SLST (r= 0.805, p= 9.7 x 10-5)  and FGS (r= 0.779, 





The D/D genotype group had fewer significant correlations with MSL. A fair 
negative relationship was found with LE response time (r= -0.435, p= 0.038); moderate 
negative relationships with RST (r= -0.508, p= 0.016) and FSST (r= -0.634, p= 0.002); a 
fair positive relationship with UGS (r= 0.446, p= 0.033); and moderate positive 
relationships with SLST (r= 0.554, p= 0.006) and FGS (r= 0.577, p= 0.005). There were 
no significant correlations between MSL and any strength measures for the D/D genotype 
group. This suggests that assessments of lower body strength based on MSL would not be 
reliable for this group. 
SLST 
The presence of significant correlations for SLST follow a similar pattern as those 
of MSL, with no significant correlations with strength measure in the D/D group, while 
significant correlations existed for all measures in the I/D group and all measures but LE 
response time, STS, and Grip Strength in the I/I group. In the I/D group, SLST had fair 
negative relationships with LE response time (r= -0.494, p= 3.58 x 10-4), STS (r= -0.330, 
p= 0.023), and FSST (r= -0.458, p= 0.001); a moderate negative relationship with RST 
(r= -0.552, p= 5.8 x 10-5); fair positive relationships with Hip Flex (r=0.452 , p= 0.001), 
Knee Extension (r= 0.369, p= 0.012), Ankle Flex (r= 0.452, p= 0.001), Composite 
Strength (r= 0.458, p= 0.001), and Grip Strength (r= 0.478, p= 0.001); and moderate 
positive relationships with MSL (r= 0.609, p= 4.0 x 10-6), UGS (r= 0.553, p= 4.5 x 10-5), 
and FGS (r= 0.533, p= 9.5 x 10-5).  
The I/I group had good negative relationships between SLST and RST (r= -0.678, 
p= 0.003), and FSST (r= -0.775, p= 2.61 x 10-4) moderate positive relationships between 





Flex (r= 0.632, p= 0.006), Composite Strength (r= 0.610, p= 0.009), UGS (r= 0.587, p= 
0.013), and FGS (r= 0.617, p= 0.008); and a good positive relationship between SLST 
and MSL (r= 0.805, p= < 0.001).  
For the D/D genotype group, SLST had a fair negative relationship with FSST (r= 
-0.430, p= 0.046); moderate negative relationships with LE response time (r= -0.569, p= 
0.005) and RST (r= -0.523, p= 0.013); moderate positive relationships with MSL (r= 
0.554, p= 0.006) and UGS (r= 0.571, p= 0.004); and a good positive relationship with 
FGS (r= 0.678, p= 0.001). 
FSST 
The D/D genotype group had fewer significant correlations between FSST and 
other measures than other groups, lacking significant correlations with any strength 
measure except for Grip Strength. The was a fair negative relationship found between 
FSST and SLST (r= -0.430, p= 0.46); moderate negative relationships with MSL (r=        
-0.634, p= 0.002), Grip Strength (r= -0.543, p= 0.009), and UGS (r= -0.598, p= 0.003); a 
good negative relationship with FGS (r= -0.710, p= 2.16 x 10-4); a moderate positive 
relationship with LE response time (r= 0.516, p= 0.014); and a good positive relationship 
with RST (r= 0.730, p= 1.16 x 10-4).  
The I/I genotype group had significant correlations between FSST all physical 
measures except LE response time, STS, Knee Extension, and Ankle Flex. FSST had 
moderate negative relationships with Hip Flex (r= -0.600, p= 0.011), Composite Strength 
(r= -0.534, p= 0.027), Grip Strength (r= -0.627, p= 0.007), and UGS (r= -0.645, p= 





p= 1.9 x 10-5), SLST (r= -0.775, p= 2.61 x 10-4), and FGS (r= -0.733, p= 0.001); and a 
good positive relationship with RST (r= 0.775, p= 2.62 x 10-4).  
In the I/D group, significant correlations were found between FSST and all other 
physical measures. There were fair negative relationships with SLST (r= -0.548, p= 
0.001), Hip Flex (r= -0.425, p= 0.003), Knee Extension (r= -0.450, p= 0.001), Ankle Flex 
(r= -0.417, p= 0.003), and Grip Strength (r= -0.394, p= 0.006); a moderate negative 
relationship with Composite Strength (r= -0.497, p= 3.25 x 10-4) and UGS (r= -0.663, p= 
2.85 x 10-7; and good negative relationships with MSL (r= -0.706, p= 2.14 x 10-8) and 
FGS (r= -0.786, p= 3.29 x 10-11). There was also a fair positive relationship between 
FSST and LE response time (r= 0.479, p= 0.001); a moderate positive relationship with 
STS (r= 0.623, p= 3.0 x 10-6); and a good positive relationship with RST (r= 0.704, p= 
3.47 x 10-8). 
UGS and FGS 
The significant correlations of UGS and FGS with other physical activity 
measures have already be covered, but there were also differences in the significant 
correlations of FGS and UGS with physical strength measures between the genotype 
groups. In the I/D genotype group, UGS correlated with all the strength measures. A fair 
positive relationship was observed with Knee Extension (r= 0.464, p= 0.001); and 
moderate positive relationships with Hip Flex (r= 0.515, p= 1.83 x 10-4), Ankle Flex (r= 
0.565, p= 2.9 x 10-5), Composite Strength (r= 0.583, p= 1.3 x 10-5), and Grip Strength (r= 
0.604, p= 6.0 x 10-6). FGS also had correlations in the I/D group, showing moderate 
positive relationships with with Hip Flex (r= 0.534, p= 9.2 x 10-5), Knee Extension (r= 





0.624, p= 2.0 x 10-6), and Grip Strength (r= 0.539, p= 7.7 x 10-5). UGS and FGS also had 
a good positive relationship with each other (r= 0.811, p= 2.82 x 10-12). Additionally, 
there were moderate negative relationships between BMI and both UGS (r= -0.532, p= 
1.38 x 10-4) and FGS (r= 0.531, p= 1.03 x 10-4) in the I/D group that were not found in 
other groups. 
 In the D/D genotype group, FGS had a fair positive relationship with Ankle 
Strength (r= 0.484, p= 0.023); moderate positive relationships with Hip Flex (r= 0.600, 
p= 0.003), Knee Extension (r= 0.615, p= 0.002), and Composite Strength (r= 0.550, p= 
0.008); and a good positive relationship with Grip Strength (r= 0.689, p= 3.94 x 10-4). For 
UGS in the D/D group, there was just a fair positive relationship with Composite 
Strength (r= 0.442, p= 0.035); and moderate positive relationships with Knee Extension 
(r= 0.546, p= 0.007) and Grip Strength (r= 0.676, p= 4.04 x 10-4). FGS and UGS also had 
a strong positive correlation with each other (r= 0.869, p= 1.56 x 10-7), but none with 
BMI.  
In the I/I genotype group, there was only a moderate strong relationship between 
FGS and Hip Strength (r= 0.507, p= 0.038). FGS did not correlate with any other strength 
measures, and UGS did not correlate with any strength measures at all, although FGS and 
UGS did correlate with each other with a excellent positive relationship (r= 0.945, p= 







Additionally, Ankle Flex had fair negative relationships with being a faller (r=      
-0.312, p= 0.031) and the number of falls in the last 12 months (r= -0.317, p= 0.028) in 
the I/D genotype group, but not in the other groups. 
 
Discussion 
Among the different ACE genotype groups, there were numerous instances of 
differential correlations among the physical performance and strength measures. When 
the categories of the measures were considered, some interesting patterns are observed. 
By taking these disparate relationships into account during physical therapy, and general 
exercise for older adults, workout regimens that would impart the most benefit could be 
prescribed to patients based on their ACE genotype. If the goal was to improve or 
maintain balance, for instance, focusing on strengthening the leg muscles may not be 
useful for those with a D/D genotype. A previous study found that compared to the D/D 
genotype, I/I and I/D had weak positive significant interactions with Grip Strength and 
FGS (Yoshihara et al., 2009). However, in this study no differences were found for any 
variables between genotypes. 
The Lower Extremity (LE) response time test was significantly correlated with 
balance measures like the Four-Square Step Test (FSST) and the Single Leg Stand Time 
(SLST) test, as well as to the Max Step Length (MSL) test and the Sit to Stand (STS) test, 
in the I/D and D/D genotype groups, but not in I/I. When considering the entire sample as 
a whole, not based on ACE genotype, there were significant correlations with these 
measures as well. If interventions or further studies were undertaken based on those 





results, as the non-correlations in I/I would be affecting the overall results, hiding 
possible stronger correlations in the other genotypes groups. The lack of correlation 
between LE response time and other physical performance measures in the I/I group in 
this study provides evidence that a lack of ACE activity may play a role, as the I allele is 
associated with less ACE mRNA being produced. This also seems to corroborate 
previous results which found that for physically active older adults, the I/I genotype 
group was more likely to develop mobility limitations (Krichevsky et al., 2005) 
When considering balance measures themselves like FSST and SLST, differential 
significant correlations were also seen. SLST had positive significant correlations and 
FSST had negative significant correlations with all the strength measures (Hip Flex, Knee 
Extension, Ankle Flex, Composite Strength, and Grip Strength) in the I/D group, 
indicating strength was linked to better times in each test. In the I/I group, SLST had 
positive significant correlations with all the strength measures except Grip Strength. 
FSST had negative significant correlations with all the strength measures except Knee 
Extension and Ankle Flex, suggesting that strengthening the knees and ankles of those 
with the I/I genotype may not help balance, but strengthening the hips might lead to 
balance improvements. These balance measures did not have any significant correlations 
with any strength measures in the D/D group. This indicates that exercising and 
strengthening the legs of older individuals may not improve balance if they have the D/D 
genotype, and this relationship may apply to physical therapy in younger patients as well, 
although further study would be needed to corroborate this possibility. Interestingly, a 
previous study found that over the course of 18-months of isokinetic knee strength 





2008). Taken together, the D/D group may respond better to certain types of training than 
the other groups, but this may not necessarily improve balance. Since the D allele is 
associated with more mRNA being produced and the D/D genotype is linked with more 
activated Ang II, this seems to suggest that ACE activity and involved pathways have a 
complex relationship with balance, lower body strength, and their correlations. Future 
studies should examine this relationship and mechanisms involved.  
MSL, UGS, and FGS were all significantly correlated with the strength measures 
when considering the complete sample. However, the relationships were more complex 
when considering ACE genotype. MSL had positive correlations with all the strength 
measures in the I/I and I/D groups, but no correlations in the D/D group. However, FGS 
had positive significant correlations with all the strength measure in I/D and D/D, but 
only with Hip Flex in I/I. UGS had positive significant correlations with all strength 
measures in I/D and with all strength measures except Hip Flex and Ankle Flex in D/D, 
but there were no significant correlations with strength measures in I/I. If examining 
stepping and gait, either in a study or as part of physical therapy, not taking ACE 
genotype into account could muddle results, perhaps severely, especially if strength was 
being considered as well. In physical therapy, focusing on strength to improve stepping 
and gait could have vastly different effects depending on ACE genotype, as stepping and 
gait themselves relate to each other differently depending on genotype. Additionally, 
future studies could examine the role ACE activity plays, as the lack of correlations of 
MSL with strength in the D/D group and of UGS and FGS with strength in the I/I group 





The differential significant correlations also call into question the usefulness and 
validity of some tests. For instance, the STS test had various significant correlations with 
the other measures in the complete sample and in the I/D group, such as negative 
significant correlations with the strength measures, indicating strength was associated 
with shorter times for the test. However, there were only significant correlations with Hip 
Flex and Grip Strength in D/D, and no significant correlations with any strength measures 
in I/I. This seems to indicate that for those with the I/I genotype, the STS test may be less 
useful for evaluating strength than for those with other genotypes. Additionally, STS had 
various significant correlations with MSL, SLST, FSST, UGS, and FGS in the complete 
sample and the I/D group, but only significant correlations with UGS in I/I and with UGS 
and FGS in D/D. This suggests that physical therapy, especially in older adults, should be 
tailored to patients based on their ACE genotype to obtain the best results. 
The differential significant correlations among the ACE genotype groups suggest 
that for elderly patients, and perhaps for others, exercise and physical therapy should be 
tailored to ACE genotype. With the complex role ACE plays in the musculoskeletal and 
cardiovascular systems, it is not hard to imagine that different cardiovascular and 
muscular responses during and after activity due to genotype could have measurable 
effects. Without considering these effects, physical therapies may not have the desired 
effect, or could even be detrimental. Lack of significant correlations, for instance 
between strength measures and balance or gait measures, suggest that physical therapies 
focusing on improving those measures or using them in evaluations may be flawed 
without realizing it. When studies use entire groups, not considering genotypes such as 





Though this study was limited by its small size and must be expanded for 
anything definitive to be concluded, the results hint at the complex interplays of various 
genes with physical health and exercise that are only now being considered. This study 
also only looked at a single polymorphism in the ACE gene, the Alu insertion, though 
others do exist, some of which are known to affect ACE serum levels. It was also limited 
by only looking at ACE genotype and not ACE expression or serum levels.  
Studies in the future should take other ACE polymorphisms into account as well, 
as those could cause different effects from the I and D ACE alleles. Future studies could 
also look at serum levels of ACE and its activity levels. This could be done before and 
after exercise in order to examine not only the differences in serum levels between 
genotypes, but also the differences in serum level response to exercise between 
genotypes, leading to better understanding of how the genotypes react to exercise. Similar 
studies should also be carried out for all age groups, not only the elderly, to see if similar 
relationships exist. Additionally, future studies should attempt to elucidate the role of 
ACE activity and the mechanism at play hinted at in the correlations. When the I/I or D/D 
groups lack correlations seen elsewhere, this suggests that too much or too little ACE 
activity may be playing a role. Understanding the role of ACE is important not only for 
physical therapy and exercise, but also for knowing how patients may react to 
medications such as ACE inhibitors, especially when they may be taken over long 
periods of time. If inhibiting ACE activity may be having long term physical effects on 
the cardiovascular and musculoskeletal systems, it is something that should be known 





to show that the relationships between physical performance and strength measures differ 
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.455** -.255* .079 .220* .214* .214* .172 .291** 1.000 .524** .699** -.533** -.500** .481** -.462** -.432** -.336** -.439** -.493** -.539** -.619** 
Sig. (2-tailed) .000 .017 .462 .039 .045 .046 .109 .006 . .000 .000 .000 .000 .000 .000 .000 .001 .000 .000 .000 .000 
N 88 88 88 88 88 88 88 88 88 86 86 88 88 87 88 88 88 88 88 88 87 
STS_Best Correlation 
Coefficient 
.240* .028 .314** .341** .035 .078 .076 .276* .524** 1.000 .612** -.513** -.376** .534** -.537** -.459** -.427** -.507** -.456** -.574** -.557** 
Sig. (2-tailed) .026 .799 .003 .001 .750 .478 .489 .010 .000 . .000 .000 .000 .000 .000 .000 .000 .000 .000 .000 .000 
N 86 86 86 86 86 86 86 86 86 86 85 86 86 86 86 86 86 86 86 86 86 
RST_Best Correlation 
Coefficient 
.402** -.242* .203 .323** .280** .244* .191 .293** .699** .612** 1.000 -.709** -.560** .728** -.455** -.524** -.480** -.535** -.481** -.684** -.743** 
Sig. (2-tailed) .000 .025 .060 .002 .009 .024 .078 .006 .000 .000 . .000 .000 .000 .000 .000 .000 .000 .000 .000 .000 





-.362** .254* -.136 -.276** -.165 -.152 -.123 -.324** -.533** -.513** -.709** 1.000 .626** -.720** .394** .481** .438** .468** .405** .572** .711** 
Sig. (2-tailed) .001 .017 .205 .009 .124 .158 .252 .002 .000 .000 .000 . .000 .000 .000 .000 .000 .000 .000 .000 .000 
N 88 88 88 88 88 88 88 88 88 86 86 88 88 87 88 88 88 88 88 88 87 
SLST_Best Correlation 
Coefficient 
-.477** .211* -.230* -.376** -.330** -.318** -.279** -.337** -.500** -.376** -.560** .626** 1.000 -.524** .405** .387** .453** .437** .475** .552** .549** 
Sig. (2-tailed) .000 .048 .031 .000 .002 .003 .008 .001 .000 .000 .000 .000 . .000 .000 .000 .000 .000 .000 .000 .000 
N 88 88 88 88 88 88 88 88 88 86 86 88 88 87 88 88 88 88 88 88 87 
FSST_Best Correlation 
Coefficient 
.377** -.221* .130 .279** .249* .220* .173 .258* .481** .534** .728** -.720** -.524** 1.000 -.415** -.459** -.431** -.470** -.446** -.653** -.768** 
Sig. (2-tailed) .000 .040 .229 .009 .020 .041 .109 .016 .000 .000 .000 .000 .000 . .000 .000 .000 .000 .000 .000 .000 
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-.057 -.014 -.564** -.631** -.203 -.269* -.253* -.383** -.462** -.537** -.455** .394** .405** -.415** 1.000 .712** .666** .857** .639** .472** .500** 
Sig. (2-tailed) .597 .898 .000 .000 .058 .011 .018 .000 .000 .000 .000 .000 .000 .000 . .000 .000 .000 .000 .000 .000 





-.084 -.091 -.530** -.527** -.148 -.115 -.080 -.315** -.432** -.459** -.524** .481** .387** -.459** .712** 1.000 .766** .933** .521** .483** .504** 
Sig. (2-tailed) .439 .397 .000 .000 .169 .284 .459 .003 .000 .000 .000 .000 .000 .000 .000 . .000 .000 .000 .000 .000 





-.078 -.005 -.589** -.622** -.188 -.204 -.178 -.278** -.336** -.427** -.480** .438** .453** -.431** .666** .766** 1.000 .883** .592** .475** .537** 
Sig. (2-tailed) .468 .964 .000 .000 .079 .057 .097 .009 .001 .000 .000 .000 .000 .000 .000 .000 . .000 .000 .000 .000 





-.064 -.043 -.601** -.638** -.175 -.188 -.160 -.359** -.439** -.507** -.535** .468** .437** -.470** .857** .933** .883** 1.000 .625** .525** .565** 
Sig. (2-tailed) .554 .691 .000 .000 .103 .079 .137 .001 .000 .000 .000 .000 .000 .000 .000 .000 .000 . .000 .000 .000 





-.231* .384** -.317** -.563** -.241* -.246* -.222* -.353** -.493** -.456** -.481** .405** .475** -.446** .639** .521** .592** .625** 1.000 .543** .491** 
Sig. (2-tailed) .031 .000 .003 .000 .024 .021 .037 .001 .000 .000 .000 .000 .000 .000 .000 .000 .000 .000 . .000 .000 
N 88 88 88 88 88 88 88 88 88 86 86 88 88 87 88 88 88 88 88 88 87 
Best_UGS Correlation 
Coefficient 
-.403** .253* -.226* -.370** -.172 -.124 -.087 -.357** -.539** -.574** -.684** .572** .552** -.653** .472** .483** .475** .525** .543** 1.000 .837** 
Sig. (2-tailed) .000 .018 .034 .000 .109 .249 .421 .001 .000 .000 .000 .000 .000 .000 .000 .000 .000 .000 .000 . .000 
N 88 88 88 88 88 88 88 88 88 86 86 88 88 87 88 88 88 88 88 88 87 
Best_FGS Correlation 
Coefficient 
-.425** .288** -.260* -.423** -.169 -.131 -.087 -.370** -.619** -.557** -.743** .711** .549** -.768** .500** .504** .537** .565** .491** .837** 1.000 
Sig. (2-tailed) .000 .007 .015 .000 .117 .227 .424 .000 .000 .000 .000 .000 .000 .000 .000 .000 .000 .000 .000 .000 . 





































































.640** -.323* .228 .317* .137 .245 .242 .109 1.000 .500** .752** -.622** -.494** .479** -.384** -.344* -.244 -.334* -.457** -.525** -.615** 
Sig. (2-tailed) .000 .025 .120 .028 .352 .093 .097 .460 . .000 .000 .000 .000 .001 .007 .017 .094 .020 .001 .000 .000 
N 48 48 48 48 48 48 48 48 48 47 47 48 48 48 48 48 48 48 48 48 48 
STS_Best Correlation 
Coefficient 
.264 -.012 .388** .413** .065 .147 .152 .240 .500** 1.000 .718** -.599** -.330* .623** -.592** -.472** -.431** -.560** -.443** -.557** -.560** 
Sig. (2-tailed) .073 .938 .007 .004 .666 .324 .306 .104 .000 . .000 .000 .023 .000 .000 .001 .002 .000 .002 .000 .000 
N 47 47 47 47 47 47 47 47 47 47 46 47 47 47 47 47 47 47 47 47 47 
RST_Best Correlation 
Coefficient 
.616** -.282 .356* .432** .230 .294* .264 .214 .752** .718** 1.000 -.759** -.552** .704** -.409** -.468** -.438** -.492** -.472** -.640** -.703** 
Sig. (2-tailed) .000 .055 .014 .002 .121 .045 .073 .149 .000 .000 . .000 .000 .000 .004 .001 .002 .000 .001 .000 .000 





-.434** .241 -.368* -.472** -.109 -.142 -.134 -.311* -.622** -.599** -.759** 1.000 .609** -.706** .455** .503** .499** .521** .463** .601** .732** 
Sig. (2-tailed) .002 .099 .010 .001 .461 .337 .364 .031 .000 .000 .000 . .000 .000 .001 .000 .000 .000 .001 .000 .000 
N 48 48 48 48 48 48 48 48 48 47 47 48 48 48 48 48 48 48 48 48 48 
SLST_Best Correlation 
Coefficient 
-.619** .173 -.411** -.488** -.376** -.380** -.314* -.226 -.494** -.330* -.552** .609** 1.000 -.458** .452** .360* .452** .458** .478** .553** .533** 
Sig. (2-tailed) .000 .240 .004 .000 .008 .008 .030 .122 .000 .023 .000 .000 . .001 .001 .012 .001 .001 .001 .000 .000 
N 48 48 48 48 48 48 48 48 48 47 47 48 48 48 48 48 48 48 48 48 48 
FSST_Best Correlation 
Coefficient 
.460** -.160 .320* .419** .137 .152 .120 .278 .479** .623** .704** -.706** -.458** 1.000 -.425** -.450** -.417** -.497** -.394** -.663** -.786** 
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Sig. (2-tailed) .001 .277 .027 .003 .352 .302 .415 .056 .001 .000 .000 .000 .001 . .003 .001 .003 .000 .006 .000 .000 





-.192 .036 -.578** -.654** -.129 -.227 -.239 -.397** -.384** -.592** -.409** .455** .452** -.425** 1.000 .660** .620** .841** .625** .515** .534** 
Sig. (2-tailed) .190 .806 .000 .000 .382 .121 .101 .005 .007 .000 .004 .001 .001 .003 . .000 .000 .000 .000 .000 .000 





-.244 -.087 -.643** -.623** -.101 -.149 -.146 -.351* -.344* -.472** -.468** .503** .360* -.450** .660** 1.000 .693** .901** .457** .464** .507** 
Sig. (2-tailed) .095 .555 .000 .000 .495 .312 .322 .015 .017 .001 .001 .000 .012 .001 .000 . .000 .000 .001 .001 .000 





-.284 .140 -.663** -.735** -.202 -.317* -.312* -.301* -.244 -.431** -.438** .499** .452** -.417** .620** .693** 1.000 .861** .611** .565** .636** 
Sig. (2-tailed) .051 .342 .000 .000 .169 .028 .031 .038 .094 .002 .002 .000 .001 .003 .000 .000 . .000 .000 .000 .000 





-.276 .043 -.675** -.734** -.149 -.253 -.254 -.390** -.334* -.560** -.492** .521** .458** -.497** .841** .901** .861** 1.000 .618** .583** .624** 
Sig. (2-tailed) .057 .774 .000 .000 .311 .083 .081 .006 .020 .000 .000 .000 .001 .000 .000 .000 .000 . .000 .000 .000 





-.364* .437** -.440** -.677** -.258 -.319* -.291* -.361* -.457** -.443** -.472** .463** .478** -.394** .625** .457** .611** .618** 1.000 .604** .539** 
Sig. (2-tailed) .011 .002 .002 .000 .076 .027 .045 .012 .001 .002 .001 .001 .001 .006 .000 .001 .000 .000 . .000 .000 
N 48 48 48 48 48 48 48 48 48 47 47 48 48 48 48 48 48 48 48 48 48 
Best_UGS Correlation 
Coefficient 
-.526** .385** -.331* -.523** -.165 -.131 -.081 -.362* -.525** -.557** -.640** .601** .553** -.663** .515** .464** .565** .583** .604** 1.000 .811** 
Sig. (2-tailed) .000 .007 .021 .000 .261 .375 .583 .011 .000 .000 .000 .000 .000 .000 .000 .001 .000 .000 .000 . .000 
N 48 48 48 48 48 48 48 48 48 47 47 48 48 48 48 48 48 48 48 48 48 
Best_FGS Correlation 
Coefficient 
-.584** .304* -.396** -.531** -.095 -.144 -.126 -.324* -.615** -.560** -.703** .732** .533** -.786** .534** .507** .636** .624** .539** .811** 1.000 
Sig. (2-tailed) .000 .036 .005 .000 .521 .330 .392 .025 .000 .000 .000 .000 .000 .000 .000 .000 .000 .000 .000 .000 . 
N 48 48 48 48 48 48 48 48 48 47 47 48 48 48 48 48 48 48 48 48 48 
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.528** -.351 -.133 .043 .467* .252 .191 .509* 1.000 .516* .645** -.435* -.569** .516* -.541** -.493* -.419* -.482* -.684** -.567** -.697** 
Sig. (2-tailed) .010 .101 .545 .844 .025 .246 .383 .013 . .014 .001 .038 .005 .014 .008 .017 .047 .020 .000 .005 .000 
N 23 23 23 23 23 23 23 23 23 22 22 23 23 22 23 23 23 23 23 23 22 
STS_Best Correlation 
Coefficient 
.420 .049 .241 .286 .073 .162 .154 .260 .516* 1.000 .430* -.297 -.314 .379 -.567** -.360 -.277 -.406 -.644** -.584** -.600** 
Sig. (2-tailed) .052 .828 .279 .197 .747 .471 .494 .242 .014 . .046 .180 .155 .082 .006 .099 .211 .061 .001 .004 .003 
N 22 22 22 22 22 22 22 22 22 22 22 22 22 22 22 22 22 22 22 22 22 
RST_Best Correlation 
Coefficient 
.376 -.237 -.009 .147 .407 .128 .060 .223 .645** .430* 1.000 -.508* -.523* .730** -.484* -.531* -.440* -.495* -.597** -.692** -.775** 
Sig. (2-tailed) .084 .288 .968 .513 .060 .571 .791 .319 .001 .046 . .016 .013 .000 .022 .011 .041 .019 .003 .000 .000 





-.484* .408 .241 .147 -.272 -.140 -.111 -.079 -.435* -.297 -.508* 1.000 .554** -.634** .225 .390 .216 .243 .325 .446* .577** 
Sig. (2-tailed) .019 .053 .267 .503 .208 .525 .613 .719 .038 .180 .016 . .006 .002 .301 .066 .321 .264 .130 .033 .005 
N 23 23 23 23 23 23 23 23 23 22 22 23 23 22 23 23 23 23 23 23 22 
SLST_Best Correlation 
Coefficient 
-.430* .465* .035 -.139 -.118 .021 .040 -.441* -.569** -.314 -.523* .554** 1.000 -.430* .231 .344 .287 .256 .484* .571** .678** 
Sig. (2-tailed) .041 .025 .873 .528 .592 .925 .856 .035 .005 .155 .013 .006 . .046 .288 .108 .184 .238 .019 .004 .001 
N 23 23 23 23 23 23 23 23 23 22 22 23 23 22 23 23 23 23 23 23 22 
FSST_Best Correlation 
Coefficient 
.480* -.315 -.164 -.002 .449* .248 .197 -.186 .516* .379 .730** -.634** -.430* 1.000 -.347 -.421 -.294 -.321 -.543** -.598** -.710** 
Sig. (2-tailed) .024 .154 .466 .994 .036 .266 .380 .408 .014 .082 .000 .002 .046 . .113 .051 .184 .145 .009 .003 .000 
41 
 





-.037 -.144 -.538** -.599** -.331 -.321 -.302 -.159 -.541** -.567** -.484* .225 .231 -.347 1.000 .794** .776** .913** .740** .410 .600** 
Sig. (2-tailed) .866 .512 .008 .003 .123 .135 .161 .469 .008 .006 .022 .301 .288 .113 . .000 .000 .000 .000 .052 .003 





-.149 -.088 -.473* -.512* -.331 -.207 -.175 -.064 -.493* -.360 -.531* .390 .344 -.421 .794** 1.000 .826** .941** .655** .546** .615** 
Sig. (2-tailed) .497 .691 .023 .013 .123 .342 .425 .773 .017 .099 .011 .066 .108 .051 .000 . .000 .000 .001 .007 .002 





.066 -.081 -.539** -.596** -.253 -.110 -.079 -.079 -.419* -.277 -.440* .216 .287 -.294 .776** .826** 1.000 .913** .710** .387 .484* 
Sig. (2-tailed) .766 .715 .008 .003 .244 .617 .719 .719 .047 .211 .041 .321 .184 .184 .000 .000 . .000 .000 .068 .023 





-.001 -.162 -.584** -.616** -.292 -.203 -.175 -.079 -.482* -.406 -.495* .243 .256 -.321 .913** .941** .913** 1.000 .734** .442* .550** 
Sig. (2-tailed) .996 .461 .003 .002 .176 .352 .425 .719 .020 .061 .019 .264 .238 .145 .000 .000 .000 . .000 .035 .008 





-.312 .182 -.249 -.343 -.331 -.169 -.127 -.191 -.684** -.644** -.597** .325 .484* -.543** .740** .655** .710** .734** 1.000 .676** .689** 
Sig. (2-tailed) .147 .406 .253 .109 .123 .440 .563 .383 .000 .001 .003 .130 .019 .009 .000 .001 .000 .000 . .000 .000 
N 23 23 23 23 23 23 23 23 23 22 22 23 23 22 23 23 23 23 23 23 22 
Best_UGS Correlation 
Coefficient 
-.516* .228 -.114 -.232 -.195 -.071 -.048 -.223 -.567** -.584** -.692** .446* .571** -.598** .410 .546** .387 .442* .676** 1.000 .869** 
Sig. (2-tailed) .012 .294 .604 .286 .373 .747 .829 .307 .005 .004 .000 .033 .004 .003 .052 .007 .068 .035 .000 . .000 
N 23 23 23 23 23 23 23 23 23 22 22 23 23 22 23 23 23 23 23 23 22 
Best_FGS Correlation 
Coefficient 
-.483* .364 -.133 -.373 -.376 -.249 -.205 -.242 -.697** -.600** -.775** .577** .678** -.710** .600** .615** .484* .550** .689** .869** 1.000 
Sig. (2-tailed) .023 .096 .556 .087 .085 .263 .359 .279 .000 .003 .000 .005 .001 .000 .003 .002 .023 .008 .000 .000 . 



































































-.178 -.138 .059 .203 .094 .059 .000 .580* 1.000 .456 .547* -.240 -.363 .409 -.574* -.529* -.583* -.642** -.525* -.447 -.429 
Sig. (2-tailed) .494 .598 .823 .434 .718 .821 1.000 .015 . .066 .023 .353 .152 .103 .016 .029 .014 .005 .031 .072 .086 
N 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 
STS_Best Correlation 
Coefficient 
-.038 .340 .262 .056 -.220 -.207 -.211 .316 .456 1.000 .355 -.451 -.447 .397 -.333 -.431 -.471 -.400 -.225 -.539* -.424 
Sig. (2-tailed) .885 .182 .309 .830 .395 .425 .417 .216 .066 . .162 .069 .072 .115 .191 .084 .057 .112 .384 .026 .090 
N 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 
RST_Best Correlation 
Coefficient 
-.192 -.236 .159 .402 .283 .369 .343 .738** .547* .355 1.000 -.757** -.678** .775** -.657** -.566* -.603* -.674** -.512* -.896** -.909** 
Sig. (2-tailed) .461 .361 .541 .110 .270 .145 .178 .001 .023 .162 . .000 .003 .000 .004 .018 .010 .003 .036 .000 .000 





-.056 .128 -.181 -.343 -.220 -.277 -.264 -.580* -.240 -.451 -.757** 1.000 .805** -.846** .618** .498* .485* .569* .510* .667** .779** 
Sig. (2-tailed) .830 .624 .486 .178 .395 .281 .307 .015 .353 .069 .000 . .000 .000 .008 .042 .048 .017 .037 .003 .000 
N 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 
SLST_Best Correlation 
Coefficient 
-.295 .117 -.094 -.279 -.457 -.587* -.573* -.519* -.363 -.447 -.678** .805** 1.000 -.775** .533* .569* .632** .610** .404 .587* .617** 
Sig. (2-tailed) .250 .654 .720 .278 .065 .013 .016 .033 .152 .072 .003 .000 . .000 .027 .017 .006 .009 .108 .013 .008 
N 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 
FSST_Best Correlation 
Coefficient 
.095 -.416 -.034 .316 .409 .442 .422 .659** .409 .397 .775** -.846** -.775** 1.000 -.600* -.424 -.449 -.534* -.627** -.645** -.733** 
Sig. (2-tailed) .718 .097 .896 .216 .103 .076 .092 .004 .103 .115 .000 .000 .000 . .011 .090 .071 .027 .007 .005 .001 
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.376 .084 -.471 -.667** -.157 -.146 -.079 -.738** -.574* -.333 -.657** .618** .533* -.600* 1.000 .843** .809** .941** .630** .396 .507* 
Sig. (2-tailed) .137 .749 .057 .003 .546 .575 .763 .001 .016 .191 .004 .008 .027 .011 . .000 .000 .000 .007 .115 .038 





.298 -.037 -.395 -.542* -.126 -.094 -.026 -.501* -.529* -.431 -.566* .498* .569* -.424 .843** 1.000 .875** .941** .605* .351 .370 
Sig. (2-tailed) .245 .888 .117 .025 .630 .718 .920 .041 .029 .084 .018 .042 .017 .090 .000 . .000 .000 .010 .167 .144 





.320 -.071 -.566* -.681** -.157 -.210 -.158 -.632** -.583* -.471 -.603* .485* .632** -.449 .809** .875** 1.000 .936** .525* .406 .382 
Sig. (2-tailed) .210 .785 .018 .003 .546 .418 .544 .006 .014 .057 .010 .048 .006 .071 .000 .000 . .000 .031 .106 .130 





.376 .032 -.483* -.664** -.189 -.177 -.105 -.685** -.642** -.400 -.674** .569* .610** -.534* .941** .941** .936** 1.000 .635** .423 .468 
Sig. (2-tailed) .137 .903 .050 .004 .468 .497 .687 .002 .005 .112 .003 .017 .009 .027 .000 .000 .000 . .006 .090 .058 





.221 .441 .012 -.392 -.063 .020 .053 -.474 -.525* -.225 -.512* .510* .404 -.627** .630** .605* .525* .635** 1.000 .245 .358 
Sig. (2-tailed) .394 .076 .963 .119 .810 .940 .841 .054 .031 .384 .036 .037 .108 .007 .007 .010 .031 .006 . .342 .158 
N 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 
Best_UGS Correlation 
Coefficient 
.077 .059 -.112 -.185 -.158 -.236 -.224 -.620** -.447 -.539* -.896** .667** .587* -.645** .396 .351 .406 .423 .245 1.000 .945** 
Sig. (2-tailed) .768 .821 .670 .477 .546 .361 .387 .008 .072 .026 .000 .003 .013 .005 .115 .167 .106 .090 .342 . .000 
N 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 
Best_FGS Correlation 
Coefficient 
.052 .212 -.118 -.306 -.252 -.248 -.211 -.738** -.429 -.424 -.909** .779** .617** -.733** .507* .370 .382 .468 .358 .945** 1.000 
Sig. (2-tailed) .844 .414 .653 .232 .329 .337 .417 .001 .086 .090 .000 .000 .008 .001 .038 .144 .130 .058 .158 .000 . 






































































.603** -.308** .076 .239* .236* .249* .211 .220 1.000 .507** .725** -.595** -.548** .512** -.429** -.401** -.299* -.401** -.504** -.551** -.643** 
Sig. (2-tailed) .000 .009 .526 .045 .047 .036 .077 .065 . .000 .000 .000 .000 .000 .000 .001 .011 .001 .000 .000 .000 
N 71 71 71 71 71 71 71 71 71 69 69 71 71 70 71 71 71 71 71 71 70 
STS_Best Correlation 
Coefficient 
.307* -.003 .326** .373** .071 .143 .145 .245* .507** 1.000 .637** -.522** -.337** .557** -.579** -.441** -.395** -.507** -.481** -.561** -.549** 
Sig. (2-tailed) .010 .980 .006 .002 .564 .240 .236 .043 .000 . .000 .000 .005 .000 .000 .000 .001 .000 .000 .000 .000 
N 69 69 69 69 69 69 69 69 69 69 68 69 69 69 69 69 69 69 69 69 69 
RST_Best Correlation 
Coefficient 
.530** -.253* .210 .324** .274* .226 .172 .193 .725** .637** 1.000 -.698** -.539** .723** -.416** -.492** -.453** -.492** -.471** -.644** -.723** 
Sig. (2-tailed) .000 .036 .083 .007 .023 .062 .158 .113 .000 .000 . .000 .000 .000 .000 .000 .000 .000 .000 .000 .000 





-.441** .279* -.131 -.270* -.146 -.123 -.097 -.248* -.595** -.522** -.698** 1.000 .586** -.675** .357** .474** .417** .434** .385** .531** .687** 
Sig. (2-tailed) .000 .019 .277 .023 .224 .307 .421 .037 .000 .000 .000 . .000 .000 .002 .000 .000 .000 .001 .000 .000 
N 71 71 71 71 71 71 71 71 71 69 69 71 71 70 71 71 71 71 71 71 70 
SLST_Best Correlation 
Coefficient 
-.537** .231 -.246* -.410** -.304* -.251* -.206 -.294* -.548** -.337** -.539** .586** 1.000 -.444** .376** .349** .401** .395** .475** .547** .543** 
Sig. (2-tailed) .000 .052 .039 .000 .010 .035 .084 .013 .000 .005 .000 .000 . .000 .001 .003 .001 .001 .000 .000 .000 
N 71 71 71 71 71 71 71 71 71 69 69 71 71 70 71 71 71 71 71 71 70 
FSST_Best Correlation 
Coefficient 
.464** -.198 .143 .277* .219 .168 .117 .141 .512** .557** .723** -.675** -.444** 1.000 -.372** -.451** -.400** -.440** -.397** -.653** -.778** 
Sig. (2-tailed) .000 .100 .237 .020 .069 .166 .335 .245 .000 .000 .000 .000 .000 . .002 .000 .001 .000 .001 .000 .000 
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-.148 -.010 -.561** -.634** -.201 -.288* -.284* -.310** -.429** -.579** -.416** .357** .376** -.372** 1.000 .677** .633** .845** .656** .484** .503** 
Sig. (2-tailed) .217 .935 .000 .000 .092 .015 .016 .008 .000 .000 .000 .002 .001 .002 . .000 .000 .000 .000 .000 .000 





-.205 -.099 -.564** -.547** -.160 -.142 -.117 -.248* -.401** -.441** -.492** .474** .349** -.451** .677** 1.000 .732** .915** .482** .504** .524** 
Sig. (2-tailed) .086 .411 .000 .000 .184 .237 .332 .037 .001 .000 .000 .000 .003 .000 .000 . .000 .000 .000 .000 .000 





-.145 .046 -.588** -.640** -.201 -.207 -.184 -.208 -.299* -.395** -.453** .417** .401** -.400** .633** .732** 1.000 .876** .607** .500** .570** 
Sig. (2-tailed) .227 .701 .000 .000 .092 .084 .124 .082 .011 .001 .000 .000 .001 .001 .000 .000 . .000 .000 .000 .000 





-.170 -.031 -.622** -.661** -.184 -.213 -.195 -.281* -.401** -.507** -.492** .434** .395** -.440** .845** .915** .876** 1.000 .626** .544** .578** 
Sig. (2-tailed) .156 .799 .000 .000 .124 .074 .102 .018 .001 .000 .000 .000 .001 .000 .000 .000 .000 . .000 .000 .000 





-.314** .366** -.375** -.608** -.270* -.296* -.271* -.329** -.504** -.481** -.471** .385** .475** -.397** .656** .482** .607** .626** 1.000 .603** .523** 
Sig. (2-tailed) .008 .002 .001 .000 .023 .012 .022 .005 .000 .000 .000 .001 .000 .001 .000 .000 .000 .000 . .000 .000 
N 71 71 71 71 71 71 71 71 71 69 69 71 71 70 71 71 71 71 71 71 70 
Best_UGS Correlation 
Coefficient 
-.508** .303* -.238* -.408** -.178 -.105 -.062 -.292* -.551** -.561** -.644** .531** .547** -.653** .484** .504** .500** .544** .603** 1.000 .810** 
Sig. (2-tailed) .000 .010 .045 .000 .138 .385 .608 .014 .000 .000 .000 .000 .000 .000 .000 .000 .000 .000 .000 . .000 
N 71 71 71 71 71 71 71 71 71 69 69 71 71 70 71 71 71 71 71 71 70 
Best_FGS Correlation 
Coefficient 
-.540** .324** -.261* -.437** -.162 -.123 -.080 -.283* -.643** -.549** -.723** .687** .543** -.778** .503** .524** .570** .578** .523** .810** 1.000 
Sig. (2-tailed) .000 .006 .029 .000 .180 .310 .510 .018 .000 .000 .000 .000 .000 .000 .000 .000 .000 .000 .000 .000 . 





































































.409** -.233 .177 .283* .132 .190 .168 .228 1.000 .511** .707** -.515** -.436** .443** -.439** -.400** -.318** -.409** -.445** -.502** -.584** 
Sig. (2-tailed) .001 .062 .157 .022 .293 .129 .181 .068 . .000 .000 .000 .000 .000 .000 .001 .010 .001 .000 .000 .000 
N 65 65 65 65 65 65 65 65 65 64 64 65 65 65 65 65 65 65 65 65 65 
STS_Best Correlation 
Coefficient 
.181 .039 .353** .363** .022 .060 .059 .277* .511** 1.000 .664** -.562** -.367** .566** -.532** -.481** -.459** -.543** -.406** -.572** -.561** 
Sig. (2-tailed) .152 .760 .004 .003 .860 .637 .643 .026 .000 . .000 .000 .003 .000 .000 .000 .000 .000 .001 .000 .000 
N 64 64 64 64 64 64 64 64 64 64 63 64 64 64 64 64 64 64 64 64 64 
RST_Best Correlation 
Coefficient 
.411** -.252* .302* .410** .248* .289* .249* .333** .707** .664** 1.000 -.766** -.571** .722** -.455** -.516** -.478** -.548** -.475** -.693** -.741** 
Sig. (2-tailed) .001 .044 .015 .001 .048 .021 .047 .007 .000 .000 . .000 .000 .000 .000 .000 .000 .000 .000 .000 .000 





-.324** .203 -.311* -.435** -.140 -.170 -.151 -.395** -.515** -.562** -.766** 1.000 .648** -.752** .470** .508** .499** .542** .462** .634** .743** 
Sig. (2-tailed) .008 .105 .012 .000 .266 .176 .231 .001 .000 .000 .000 . .000 .000 .000 .000 .000 .000 .000 .000 .000 
N 65 65 65 65 65 65 65 65 65 64 64 65 65 65 65 65 65 65 65 65 65 
SLST_Best Correlation 
Coefficient 
-.510** .153 -.350** -.439** -.396** -.438** -.386** -.304* -.436** -.367** -.571** .648** 1.000 -.549** .473** .400** .502** .494** .476** .553** .538** 
Sig. (2-tailed) .000 .223 .004 .000 .001 .000 .002 .014 .000 .003 .000 .000 . .000 .000 .001 .000 .000 .000 .000 .000 
N 65 65 65 65 65 65 65 65 65 64 64 65 65 65 65 65 65 65 65 65 65 
FSST_Best Correlation 
Coefficient 
.347** -.194 .241 .387** .207 .228 .190 .383** .443** .566** .722** -.752** -.549** 1.000 -.457** -.464** -.442** -.513** -.457** -.650** -.763** 
Sig. (2-tailed) .005 .121 .053 .001 .099 .068 .129 .002 .000 .000 .000 .000 .000 . .000 .000 .000 .000 .000 .000 .000 
47 
 





-.059 .023 -.578** -.655** -.162 -.238 -.224 -.462** -.439** -.532** -.455** .470** .473** -.457** 1.000 .702** .666** .850** .611** .486** .514** 
Sig. (2-tailed) .641 .854 .000 .000 .198 .056 .073 .000 .000 .000 .000 .000 .000 .000 . .000 .000 .000 .000 .000 .000 





-.051 -.089 -.572** -.573** -.103 -.106 -.076 -.402** -.400** -.481** -.516** .508** .400** -.464** .702** 1.000 .753** .931** .505** .447** .484** 
Sig. (2-tailed) .688 .481 .000 .000 .415 .402 .546 .001 .001 .000 .000 .000 .001 .000 .000 . .000 .000 .000 .000 .000 





-.140 .034 -.651** -.688** -.182 -.269* -.248* -.371** -.318** -.459** -.478** .499** .502** -.442** .666** .753** 1.000 .880** .581** .510** .569** 
Sig. (2-tailed) .267 .790 .000 .000 .148 .030 .046 .002 .010 .000 .000 .000 .000 .000 .000 .000 . .000 .000 .000 .000 





-.090 -.006 -.634** -.683** -.144 -.199 -.175 -.454** -.409** -.543** -.548** .542** .494** -.513** .850** .931** .880** 1.000 .613** .543** .588** 
Sig. (2-tailed) .473 .960 .000 .000 .251 .113 .164 .000 .001 .000 .000 .000 .000 .000 .000 .000 .000 . .000 .000 .000 





-.223 .445** -.344** -.614** -.221 -.251* -.229 -.382** -.445** -.406** -.475** .462** .476** -.457** .611** .505** .581** .613** 1.000 .514** .489** 
Sig. (2-tailed) .075 .000 .005 .000 .077 .044 .067 .002 .000 .001 .000 .000 .000 .000 .000 .000 .000 .000 . .000 .000 
N 65 65 65 65 65 65 65 65 65 64 64 65 65 65 65 65 65 65 65 65 65 
Best_UGS Correlation 
Coefficient 
-.360** .288* -.286* -.447** -.155 -.139 -.099 -.431** -.502** -.572** -.693** .634** .553** -.650** .486** .447** .510** .543** .514** 1.000 .846** 
Sig. (2-tailed) .003 .020 .021 .000 .217 .270 .431 .000 .000 .000 .000 .000 .000 .000 .000 .000 .000 .000 .000 . .000 
N 65 65 65 65 65 65 65 65 65 64 64 65 65 65 65 65 65 65 65 65 65 
Best_FGS Correlation 
Coefficient 
-.424** .251* -.354** -.499** -.124 -.147 -.118 -.422** -.584** -.561** -.741** .743** .538** -.763** .514** .484** .569** .588** .489** .846** 1.000 
Sig. (2-tailed) .000 .043 .004 .000 .327 .243 .351 .000 .000 .000 .000 .000 .000 .000 .000 .000 .000 .000 .000 .000 . 







 N Minimum Maximum Mean Std. Deviation 
Gender 88 .00 1.00 .7841 .41381 
Age (yrs) 88 61.00 100.00 71.9091 7.97934 
BMI 88 16.59 42.95 28.3559 5.55076 




 N Minimum Maximum Mean Std. Deviation 
Gender 48 .00 1.00 .7917 .41041 
Age (yrs) 48 63.00 89.00 71.1458 6.75715 
BMI 48 18.93 41.89 29.0307 5.76301 




 N Minimum Maximum Mean Std. Deviation 
Gender 23 .00 1.00 .7826 .42174 
Age (yrs) 23 61.00 100.00 72.9130 10.48338 
BMI 23 16.59 42.95 27.0684 6.18400 






 N Minimum Maximum Mean Std. Deviation 
Gender 17 .00 1.00 .7647 .43724 
Age (yrs) 17 62.00 84.00 72.7059 7.55616 
BMI 17 20.82 33.55 28.1924 3.68972 











  /INDEPENDENT TEST 



















  /MISSING 
SCOPE=ANALYSIS 
USERMISSING=EXCLUDE 
  /CRITERIA ALPHA=0.05  
CILEVEL=95. 
Resources Processor Time 00:00:00.53 



















































































Age (yrs) Correlation 
Coefficient 
1.000 -.308** -.227* -.102 .240* .263* .234* -.014 .455** .240* .402** -.362** -.477** .377** -.057 -.084 -.078 -.064 -.231* -.403** -.425** 
Sig. (2-tailed) . .004 .033 .344 .024 .013 .028 .896 .000 .026 .000 .001 .000 .000 .597 .439 .468 .554 .031 .000 .000 
N 88 88 88 88 88 88 88 88 88 86 86 88 88 87 88 88 88 88 88 88 87 
Height_meter Correlation 
Coefficient 
-.308** 1.000 .354** -.078 -.204 -.155 -.121 -.123 -.255* .028 -.242* .254* .211* -.221* -.014 -.091 -.005 -.043 .384** .253* .288** 
Sig. (2-tailed) .004 . .001 .471 .057 .150 .263 .255 .017 .799 .025 .017 .048 .040 .898 .397 .964 .691 .000 .018 .007 
N 88 88 88 88 88 88 88 88 88 86 86 88 88 87 88 88 88 88 88 88 87 
Weight_Kg Correlation 
Coefficient 
-.227* .354** 1.000 .874** .141 .104 .092 .265* .079 .314** .203 -.136 -.230* .130 -.564** -.530** -.589** -.601** -.317** -.226* -.260* 
Sig. (2-tailed) .033 .001 . .000 .191 .334 .394 .013 .462 .003 .060 .205 .031 .229 .000 .000 .000 .000 .003 .034 .015 
N 88 88 88 88 88 88 88 88 88 86 86 88 88 87 88 88 88 88 88 88 87 
BMI Correlation 
Coefficient 
-.102 -.078 .874** 1.000 .269* .205 .172 .342** .220* .341** .323** -.276** -.376** .279** -.631** -.527** -.622** -.638** -.563** -.370** -.423** 
Sig. (2-tailed) .344 .471 .000 . .011 .055 .108 .001 .039 .001 .002 .009 .000 .009 .000 .000 .000 .000 .000 .000 .000 
N 88 88 88 88 88 88 88 88 88 86 86 88 88 87 88 88 88 88 88 88 87 
RecurrentFaller Correlation 
Coefficient 
.240* -.204 .141 .269* 1.000 .734** .562** -.057 .214* .035 .280** -.165 -.330** .249* -.203 -.148 -.188 -.175 -.241* -.172 -.169 
Sig. (2-tailed) .024 .057 .191 .011 . .000 .000 .597 .045 .750 .009 .124 .002 .020 .058 .169 .079 .103 .024 .109 .117 





Number of falls 
past 12 months 
Correlation 
Coefficient 
.263* -.155 .104 .205 .734** 1.000 .971** -.009 .214* .078 .244* -.152 -.318** .220* -.269* -.115 -.204 -.188 -.246* -.124 -.131 
Sig. (2-tailed) .013 .150 .334 .055 .000 . .000 .936 .046 .478 .024 .158 .003 .041 .011 .284 .057 .079 .021 .249 .227 
N 88 88 88 88 88 88 88 88 88 86 86 88 88 87 88 88 88 88 88 88 87 
Faller Correlation 
Coefficient 
.234* -.121 .092 .172 .562** .971** 1.000 .000 .172 .076 .191 -.123 -.279** .173 -.253* -.080 -.178 -.160 -.222* -.087 -.087 
Sig. (2-tailed) .028 .263 .394 .108 .000 .000 . 1.000 .109 .489 .078 .252 .008 .109 .018 .459 .097 .137 .037 .421 .424 
N 88 88 88 88 88 88 88 88 88 86 86 88 88 87 88 88 88 88 88 88 87 
FOF Correlation 
Coefficient 
-.014 -.123 .265* .342** -.057 -.009 .000 1.000 .291** .276* .293** -.324** -.337** .258* -.383** -.315** -.278** -.359** -.353** -.357** -.370** 
Sig. (2-tailed) .896 .255 .013 .001 .597 .936 1.000 . .006 .010 .006 .002 .001 .016 .000 .003 .009 .001 .001 .001 .000 





.455** -.255* .079 .220* .214* .214* .172 .291** 1.000 .524** .699** -.533** -.500** .481** -.462** -.432** -.336** -.439** -.493** -.539** -.619** 
Sig. (2-tailed) .000 .017 .462 .039 .045 .046 .109 .006 . .000 .000 .000 .000 .000 .000 .000 .001 .000 .000 .000 .000 
N 88 88 88 88 88 88 88 88 88 86 86 88 88 87 88 88 88 88 88 88 87 
STS_Best Correlation 
Coefficient 
.240* .028 .314** .341** .035 .078 .076 .276* .524** 1.000 .612** -.513** -.376** .534** -.537** -.459** -.427** -.507** -.456** -.574** -.557** 
Sig. (2-tailed) .026 .799 .003 .001 .750 .478 .489 .010 .000 . .000 .000 .000 .000 .000 .000 .000 .000 .000 .000 .000 
N 86 86 86 86 86 86 86 86 86 86 85 86 86 86 86 86 86 86 86 86 86 
RST_Best Correlation 
Coefficient 
.402** -.242* .203 .323** .280** .244* .191 .293** .699** .612** 1.000 -.709** -.560** .728** -.455** -.524** -.480** -.535** -.481** -.684** -.743** 
Sig. (2-tailed) .000 .025 .060 .002 .009 .024 .078 .006 .000 .000 . .000 .000 .000 .000 .000 .000 .000 .000 .000 .000 





-.362** .254* -.136 -.276** -.165 -.152 -.123 -.324** -.533** -.513** -.709** 1.000 .626** -.720** .394** .481** .438** .468** .405** .572** .711** 
Sig. (2-tailed) .001 .017 .205 .009 .124 .158 .252 .002 .000 .000 .000 . .000 .000 .000 .000 .000 .000 .000 .000 .000 







-.477** .211* -.230* -.376** -.330** -.318** -.279** -.337** -.500** -.376** -.560** .626** 1.000 -.524** .405** .387** .453** .437** .475** .552** .549** 
Sig. (2-tailed) .000 .048 .031 .000 .002 .003 .008 .001 .000 .000 .000 .000 . .000 .000 .000 .000 .000 .000 .000 .000 
N 88 88 88 88 88 88 88 88 88 86 86 88 88 87 88 88 88 88 88 88 87 
FSST_Best Correlation 
Coefficient 
.377** -.221* .130 .279** .249* .220* .173 .258* .481** .534** .728** -.720** -.524** 1.000 -.415** -.459** -.431** -.470** -.446** -.653** -.768** 
Sig. (2-tailed) .000 .040 .229 .009 .020 .041 .109 .016 .000 .000 .000 .000 .000 . .000 .000 .000 .000 .000 .000 .000 





-.057 -.014 -.564** -.631** -.203 -.269* -.253* -.383** -.462** -.537** -.455** .394** .405** -.415** 1.000 .712** .666** .857** .639** .472** .500** 
Sig. (2-tailed) .597 .898 .000 .000 .058 .011 .018 .000 .000 .000 .000 .000 .000 .000 . .000 .000 .000 .000 .000 .000 





-.084 -.091 -.530** -.527** -.148 -.115 -.080 -.315** -.432** -.459** -.524** .481** .387** -.459** .712** 1.000 .766** .933** .521** .483** .504** 
Sig. (2-tailed) .439 .397 .000 .000 .169 .284 .459 .003 .000 .000 .000 .000 .000 .000 .000 . .000 .000 .000 .000 .000 





-.078 -.005 -.589** -.622** -.188 -.204 -.178 -.278** -.336** -.427** -.480** .438** .453** -.431** .666** .766** 1.000 .883** .592** .475** .537** 
Sig. (2-tailed) .468 .964 .000 .000 .079 .057 .097 .009 .001 .000 .000 .000 .000 .000 .000 .000 . .000 .000 .000 .000 





-.064 -.043 -.601** -.638** -.175 -.188 -.160 -.359** -.439** -.507** -.535** .468** .437** -.470** .857** .933** .883** 1.000 .625** .525** .565** 
Sig. (2-tailed) .554 .691 .000 .000 .103 .079 .137 .001 .000 .000 .000 .000 .000 .000 .000 .000 .000 . .000 .000 .000 





-.231* .384** -.317** -.563** -.241* -.246* -.222* -.353** -.493** -.456** -.481** .405** .475** -.446** .639** .521** .592** .625** 1.000 .543** .491** 
Sig. (2-tailed) .031 .000 .003 .000 .024 .021 .037 .001 .000 .000 .000 .000 .000 .000 .000 .000 .000 .000 . .000 .000 







-.403** .253* -.226* -.370** -.172 -.124 -.087 -.357** -.539** -.574** -.684** .572** .552** -.653** .472** .483** .475** .525** .543** 1.000 .837** 
Sig. (2-tailed) .000 .018 .034 .000 .109 .249 .421 .001 .000 .000 .000 .000 .000 .000 .000 .000 .000 .000 .000 . .000 
N 88 88 88 88 88 88 88 88 88 86 86 88 88 87 88 88 88 88 88 88 87 
Best_FGS Correlation 
Coefficient 
-.425** .288** -.260* -.423** -.169 -.131 -.087 -.370** -.619** -.557** -.743** .711** .549** -.768** .500** .504** .537** .565** .491** .837** 1.000 
Sig. (2-tailed) .000 .007 .015 .000 .117 .227 .424 .000 .000 .000 .000 .000 .000 .000 .000 .000 .000 .000 .000 .000 . 





































































Age (yrs) Correlation 
Coefficient 
1.000 -.365* .009 .139 .206 .268 .234 -.003 .640** .264 .616** -.434** -.619** .460** -.192 -.244 -.284 -.276 -.364* -.526** -.584** 
Sig. (2-tailed) . .011 .953 .346 .159 .066 .109 .982 .000 .073 .000 .002 .000 .001 .190 .095 .051 .057 .011 .000 .000 
N 48 48 48 48 48 48 48 48 48 47 47 48 48 48 48 48 48 48 48 48 48 
Height_meter Correlation 
Coefficient 
-.365* 1.000 .216 -.197 -.148 -.185 -.151 -.045 -.323* -.012 -.282 .241 .173 -.160 .036 -.087 .140 .043 .437** .385** .304* 
Sig. (2-tailed) .011 . .140 .180 .317 .208 .306 .763 .025 .938 .055 .099 .240 .277 .806 .555 .342 .774 .002 .007 .036 
N 48 48 48 48 48 48 48 48 48 47 47 48 48 48 48 48 48 48 48 48 48 
Weight_Kg Correlation 
Coefficient 
.009 .216 1.000 .875** .357* .304* .241 .309* .228 .388** .356* -.368* -.411** .320* -.578** -.643** -.663** -.675** -.440** -.331* -.396** 





N 48 48 48 48 48 48 48 48 48 47 47 48 48 48 48 48 48 48 48 48 48 
BMI Correlation 
Coefficient 
.139 -.197 .875** 1.000 .444** .370** .278 .324* .317* .413** .432** -.472** -.488** .419** -.654** -.623** -.735** -.734** -.677** -.523** -.531** 
Sig. (2-tailed) .346 .180 .000 . .002 .010 .055 .025 .028 .004 .002 .001 .000 .003 .000 .000 .000 .000 .000 .000 .000 
N 48 48 48 48 48 48 48 48 48 47 47 48 48 48 48 48 48 48 48 48 48 
RecurrentFaller Correlation 
Coefficient 
.206 -.148 .357* .444** 1.000 .710** .466** -.164 .137 .065 .230 -.109 -.376** .137 -.129 -.101 -.202 -.149 -.258 -.165 -.095 
Sig. (2-tailed) .159 .317 .013 .002 . .000 .001 .265 .352 .666 .121 .461 .008 .352 .382 .495 .169 .311 .076 .261 .521 
N 48 48 48 48 48 48 48 48 48 47 47 48 48 48 48 48 48 48 48 48 48 
Number of falls 
past 12 months 
Correlation 
Coefficient 
.268 -.185 .304* .370** .710** 1.000 .952** -.038 .245 .147 .294* -.142 -.380** .152 -.227 -.149 -.317* -.253 -.319* -.131 -.144 
Sig. (2-tailed) .066 .208 .036 .010 .000 . .000 .797 .093 .324 .045 .337 .008 .302 .121 .312 .028 .083 .027 .375 .330 
N 48 48 48 48 48 48 48 48 48 47 47 48 48 48 48 48 48 48 48 48 48 
Faller Correlation 
Coefficient 
.234 -.151 .241 .278 .466** .952** 1.000 .027 .242 .152 .264 -.134 -.314* .120 -.239 -.146 -.312* -.254 -.291* -.081 -.126 
Sig. (2-tailed) .109 .306 .099 .055 .001 .000 . .857 .097 .306 .073 .364 .030 .415 .101 .322 .031 .081 .045 .583 .392 
N 48 48 48 48 48 48 48 48 48 47 47 48 48 48 48 48 48 48 48 48 48 
FOF Correlation 
Coefficient 
-.003 -.045 .309* .324* -.164 -.038 .027 1.000 .109 .240 .214 -.311* -.226 .278 -.397** -.351* -.301* -.390** -.361* -.362* -.324* 
Sig. (2-tailed) .982 .763 .032 .025 .265 .797 .857 . .460 .104 .149 .031 .122 .056 .005 .015 .038 .006 .012 .011 .025 





.640** -.323* .228 .317* .137 .245 .242 .109 1.000 .500** .752** -.622** -.494** .479** -.384** -.344* -.244 -.334* -.457** -.525** -.615** 
Sig. (2-tailed) .000 .025 .120 .028 .352 .093 .097 .460 . .000 .000 .000 .000 .001 .007 .017 .094 .020 .001 .000 .000 
N 48 48 48 48 48 48 48 48 48 47 47 48 48 48 48 48 48 48 48 48 48 
STS_Best Correlation 
Coefficient 
.264 -.012 .388** .413** .065 .147 .152 .240 .500** 1.000 .718** -.599** -.330* .623** -.592** -.472** -.431** -.560** -.443** -.557** -.560** 
Sig. (2-tailed) .073 .938 .007 .004 .666 .324 .306 .104 .000 . .000 .000 .023 .000 .000 .001 .002 .000 .002 .000 .000 







.616** -.282 .356* .432** .230 .294* .264 .214 .752** .718** 1.000 -.759** -.552** .704** -.409** -.468** -.438** -.492** -.472** -.640** -.703** 
Sig. (2-tailed) .000 .055 .014 .002 .121 .045 .073 .149 .000 .000 . .000 .000 .000 .004 .001 .002 .000 .001 .000 .000 





-.434** .241 -.368* -.472** -.109 -.142 -.134 -.311* -.622** -.599** -.759** 1.000 .609** -.706** .455** .503** .499** .521** .463** .601** .732** 
Sig. (2-tailed) .002 .099 .010 .001 .461 .337 .364 .031 .000 .000 .000 . .000 .000 .001 .000 .000 .000 .001 .000 .000 
N 48 48 48 48 48 48 48 48 48 47 47 48 48 48 48 48 48 48 48 48 48 
SLST_Best Correlation 
Coefficient 
-.619** .173 -.411** -.488** -.376** -.380** -.314* -.226 -.494** -.330* -.552** .609** 1.000 -.458** .452** .360* .452** .458** .478** .553** .533** 
Sig. (2-tailed) .000 .240 .004 .000 .008 .008 .030 .122 .000 .023 .000 .000 . .001 .001 .012 .001 .001 .001 .000 .000 
N 48 48 48 48 48 48 48 48 48 47 47 48 48 48 48 48 48 48 48 48 48 
FSST_Best Correlation 
Coefficient 
.460** -.160 .320* .419** .137 .152 .120 .278 .479** .623** .704** -.706** -.458** 1.000 -.425** -.450** -.417** -.497** -.394** -.663** -.786** 
Sig. (2-tailed) .001 .277 .027 .003 .352 .302 .415 .056 .001 .000 .000 .000 .001 . .003 .001 .003 .000 .006 .000 .000 





-.192 .036 -.578** -.654** -.129 -.227 -.239 -.397** -.384** -.592** -.409** .455** .452** -.425** 1.000 .660** .620** .841** .625** .515** .534** 
Sig. (2-tailed) .190 .806 .000 .000 .382 .121 .101 .005 .007 .000 .004 .001 .001 .003 . .000 .000 .000 .000 .000 .000 





-.244 -.087 -.643** -.623** -.101 -.149 -.146 -.351* -.344* -.472** -.468** .503** .360* -.450** .660** 1.000 .693** .901** .457** .464** .507** 
Sig. (2-tailed) .095 .555 .000 .000 .495 .312 .322 .015 .017 .001 .001 .000 .012 .001 .000 . .000 .000 .001 .001 .000 





-.284 .140 -.663** -.735** -.202 -.317* -.312* -.301* -.244 -.431** -.438** .499** .452** -.417** .620** .693** 1.000 .861** .611** .565** .636** 
Sig. (2-tailed) .051 .342 .000 .000 .169 .028 .031 .038 .094 .002 .002 .000 .001 .003 .000 .000 . .000 .000 .000 .000 









-.276 .043 -.675** -.734** -.149 -.253 -.254 -.390** -.334* -.560** -.492** .521** .458** -.497** .841** .901** .861** 1.000 .618** .583** .624** 
Sig. (2-tailed) .057 .774 .000 .000 .311 .083 .081 .006 .020 .000 .000 .000 .001 .000 .000 .000 .000 . .000 .000 .000 





-.364* .437** -.440** -.677** -.258 -.319* -.291* -.361* -.457** -.443** -.472** .463** .478** -.394** .625** .457** .611** .618** 1.000 .604** .539** 
Sig. (2-tailed) .011 .002 .002 .000 .076 .027 .045 .012 .001 .002 .001 .001 .001 .006 .000 .001 .000 .000 . .000 .000 
N 48 48 48 48 48 48 48 48 48 47 47 48 48 48 48 48 48 48 48 48 48 
Best_UGS Correlation 
Coefficient 
-.526** .385** -.331* -.523** -.165 -.131 -.081 -.362* -.525** -.557** -.640** .601** .553** -.663** .515** .464** .565** .583** .604** 1.000 .811** 
Sig. (2-tailed) .000 .007 .021 .000 .261 .375 .583 .011 .000 .000 .000 .000 .000 .000 .000 .001 .000 .000 .000 . .000 
N 48 48 48 48 48 48 48 48 48 47 47 48 48 48 48 48 48 48 48 48 48 
Best_FGS Correlation 
Coefficient 
-.584** .304* -.396** -.531** -.095 -.144 -.126 -.324* -.615** -.560** -.703** .732** .533** -.786** .534** .507** .636** .624** .539** .811** 1.000 
Sig. (2-tailed) .000 .036 .005 .000 .521 .330 .392 .025 .000 .000 .000 .000 .000 .000 .000 .000 .000 .000 .000 .000 . 











































































Age (yrs) Correlation 
Coefficient 
1.000 -.443* -.413 -.302 .362 .280 .248 .160 .528** .420 .376 -.484* -.430* .480* -.037 -.149 .066 -.001 -.312 -.516* -.483* 
Sig. (2-tailed) . .034 .050 .161 .089 .195 .254 .466 .010 .052 .084 .019 .041 .024 .866 .497 .766 .996 .147 .012 .023 
N 23 23 23 23 23 23 23 23 23 22 22 23 23 22 23 23 23 23 23 23 22 
Height_meter Correlation 
Coefficient 
-.443* 1.000 .569** .282 -.127 .059 .080 -.231 -.351 .049 -.237 .408 .465* -.315 -.144 -.088 -.081 -.162 .182 .228 .364 
Sig. (2-tailed) .034 . .005 .193 .565 .788 .718 .290 .101 .828 .288 .053 .025 .154 .512 .691 .715 .461 .406 .294 .096 
N 23 23 23 23 23 23 23 23 23 22 22 23 23 22 23 23 23 23 23 23 22 
Weight_Kg Correlation 
Coefficient 
-.413 .569** 1.000 .930** -.234 -.210 -.191 .064 -.133 .241 -.009 .241 .035 -.164 -.538** -.473* -.539** -.584** -.249 -.114 -.133 
Sig. (2-tailed) .050 .005 . .000 .283 .337 .383 .773 .545 .279 .968 .267 .873 .466 .008 .023 .008 .003 .253 .604 .556 
N 23 23 23 23 23 23 23 23 23 22 22 23 23 22 23 23 23 23 23 23 22 
BMI Correlation 
Coefficient 
-.302 .282 .930** 1.000 -.136 -.172 -.159 .159 .043 .286 .147 .147 -.139 -.002 -.599** -.512* -.596** -.616** -.343 -.232 -.373 
Sig. (2-tailed) .161 .193 .000 . .535 .433 .469 .469 .844 .197 .513 .503 .528 .994 .003 .013 .003 .002 .109 .286 .087 
N 23 23 23 23 23 23 23 23 23 22 22 23 23 22 23 23 23 23 23 23 22 
RecurrentFaller Correlation 
Coefficient 
.362 -.127 -.234 -.136 1.000 .809** .735** -.204 .467* .073 .407 -.272 -.118 .449* -.331 -.331 -.253 -.292 -.331 -.195 -.376 
Sig. (2-tailed) .089 .565 .283 .535 . .000 .000 .350 .025 .747 .060 .208 .592 .036 .123 .123 .244 .176 .123 .373 .085 
N 23 23 23 23 23 23 23 23 23 22 22 23 23 22 23 23 23 23 23 23 22 
Number of falls 
past 12 months 
Correlation 
Coefficient 
.280 .059 -.210 -.172 .809** 1.000 .991** -.275 .252 .162 .128 -.140 .021 .248 -.321 -.207 -.110 -.203 -.169 -.071 -.249 
Sig. (2-tailed) .195 .788 .337 .433 .000 . .000 .204 .246 .471 .571 .525 .925 .266 .135 .342 .617 .352 .440 .747 .263 
N 23 23 23 23 23 23 23 23 23 22 22 23 23 22 23 23 23 23 23 23 22 
Faller Correlation 
Coefficient 
.248 .080 -.191 -.159 .735** .991** 1.000 -.278 .191 .154 .060 -.111 .040 .197 -.302 -.175 -.079 -.175 -.127 -.048 -.205 
Sig. (2-tailed) .254 .718 .383 .469 .000 .000 . .199 .383 .494 .791 .613 .856 .380 .161 .425 .719 .425 .563 .829 .359 







.160 -.231 .064 .159 -.204 -.275 -.278 1.000 .509* .260 .223 -.079 -.441* -.186 -.159 -.064 -.079 -.079 -.191 -.223 -.242 
Sig. (2-tailed) .466 .290 .773 .469 .350 .204 .199 . .013 .242 .319 .719 .035 .408 .469 .773 .719 .719 .383 .307 .279 





.528** -.351 -.133 .043 .467* .252 .191 .509* 1.000 .516* .645** -.435* -.569** .516* -.541** -.493* -.419* -.482* -.684** -.567** -.697** 
Sig. (2-tailed) .010 .101 .545 .844 .025 .246 .383 .013 . .014 .001 .038 .005 .014 .008 .017 .047 .020 .000 .005 .000 
N 23 23 23 23 23 23 23 23 23 22 22 23 23 22 23 23 23 23 23 23 22 
STS_Best Correlation 
Coefficient 
.420 .049 .241 .286 .073 .162 .154 .260 .516* 1.000 .430* -.297 -.314 .379 -.567** -.360 -.277 -.406 -.644** -.584** -.600** 
Sig. (2-tailed) .052 .828 .279 .197 .747 .471 .494 .242 .014 . .046 .180 .155 .082 .006 .099 .211 .061 .001 .004 .003 
N 22 22 22 22 22 22 22 22 22 22 22 22 22 22 22 22 22 22 22 22 22 
RST_Best Correlation 
Coefficient 
.376 -.237 -.009 .147 .407 .128 .060 .223 .645** .430* 1.000 -.508* -.523* .730** -.484* -.531* -.440* -.495* -.597** -.692** -.775** 
Sig. (2-tailed) .084 .288 .968 .513 .060 .571 .791 .319 .001 .046 . .016 .013 .000 .022 .011 .041 .019 .003 .000 .000 





-.484* .408 .241 .147 -.272 -.140 -.111 -.079 -.435* -.297 -.508* 1.000 .554** -.634** .225 .390 .216 .243 .325 .446* .577** 
Sig. (2-tailed) .019 .053 .267 .503 .208 .525 .613 .719 .038 .180 .016 . .006 .002 .301 .066 .321 .264 .130 .033 .005 
N 23 23 23 23 23 23 23 23 23 22 22 23 23 22 23 23 23 23 23 23 22 
SLST_Best Correlation 
Coefficient 
-.430* .465* .035 -.139 -.118 .021 .040 -.441* -.569** -.314 -.523* .554** 1.000 -.430* .231 .344 .287 .256 .484* .571** .678** 
Sig. (2-tailed) .041 .025 .873 .528 .592 .925 .856 .035 .005 .155 .013 .006 . .046 .288 .108 .184 .238 .019 .004 .001 
N 23 23 23 23 23 23 23 23 23 22 22 23 23 22 23 23 23 23 23 23 22 
FSST_Best Correlation 
Coefficient 
.480* -.315 -.164 -.002 .449* .248 .197 -.186 .516* .379 .730** -.634** -.430* 1.000 -.347 -.421 -.294 -.321 -.543** -.598** -.710** 
Sig. (2-tailed) .024 .154 .466 .994 .036 .266 .380 .408 .014 .082 .000 .002 .046 . .113 .051 .184 .145 .009 .003 .000 









-.037 -.144 -.538** -.599** -.331 -.321 -.302 -.159 -.541** -.567** -.484* .225 .231 -.347 1.000 .794** .776** .913** .740** .410 .600** 
Sig. (2-tailed) .866 .512 .008 .003 .123 .135 .161 .469 .008 .006 .022 .301 .288 .113 . .000 .000 .000 .000 .052 .003 





-.149 -.088 -.473* -.512* -.331 -.207 -.175 -.064 -.493* -.360 -.531* .390 .344 -.421 .794** 1.000 .826** .941** .655** .546** .615** 
Sig. (2-tailed) .497 .691 .023 .013 .123 .342 .425 .773 .017 .099 .011 .066 .108 .051 .000 . .000 .000 .001 .007 .002 





.066 -.081 -.539** -.596** -.253 -.110 -.079 -.079 -.419* -.277 -.440* .216 .287 -.294 .776** .826** 1.000 .913** .710** .387 .484* 
Sig. (2-tailed) .766 .715 .008 .003 .244 .617 .719 .719 .047 .211 .041 .321 .184 .184 .000 .000 . .000 .000 .068 .023 





-.001 -.162 -.584** -.616** -.292 -.203 -.175 -.079 -.482* -.406 -.495* .243 .256 -.321 .913** .941** .913** 1.000 .734** .442* .550** 
Sig. (2-tailed) .996 .461 .003 .002 .176 .352 .425 .719 .020 .061 .019 .264 .238 .145 .000 .000 .000 . .000 .035 .008 





-.312 .182 -.249 -.343 -.331 -.169 -.127 -.191 -.684** -.644** -.597** .325 .484* -.543** .740** .655** .710** .734** 1.000 .676** .689** 
Sig. (2-tailed) .147 .406 .253 .109 .123 .440 .563 .383 .000 .001 .003 .130 .019 .009 .000 .001 .000 .000 . .000 .000 
N 23 23 23 23 23 23 23 23 23 22 22 23 23 22 23 23 23 23 23 23 22 
Best_UGS Correlation 
Coefficient 
-.516* .228 -.114 -.232 -.195 -.071 -.048 -.223 -.567** -.584** -.692** .446* .571** -.598** .410 .546** .387 .442* .676** 1.000 .869** 
Sig. (2-tailed) .012 .294 .604 .286 .373 .747 .829 .307 .005 .004 .000 .033 .004 .003 .052 .007 .068 .035 .000 . .000 
N 23 23 23 23 23 23 23 23 23 22 22 23 23 22 23 23 23 23 23 23 22 
Best_FGS Correlation 
Coefficient 
-.483* .364 -.133 -.373 -.376 -.249 -.205 -.242 -.697** -.600** -.775** .577** .678** -.710** .600** .615** .484* .550** .689** .869** 1.000 
Sig. (2-tailed) .023 .096 .556 .087 .085 .263 .359 .279 .000 .003 .000 .005 .001 .000 .003 .002 .023 .008 .000 .000 . 











































































Age (yrs) Correlation 
Coefficient 
1.000 .078 -.571* -.556* .126 .274 .330 -.264 -.178 -.038 -.192 -.056 -.295 .095 .376 .298 .320 .376 .221 .077 .052 
Sig. (2-tailed) . .767 .017 .020 .629 .287 .196 .306 .494 .885 .461 .830 .250 .718 .137 .245 .210 .137 .394 .768 .844 
N 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 
Height_meter Correlation 
Coefficient 
.078 1.000 .337 -.300 -.570* -.364 -.291 -.371 -.138 .340 -.236 .128 .117 -.416 .084 -.037 -.071 .032 .441 .059 .212 
Sig. (2-tailed) .767 . .185 .241 .017 .150 .257 .143 .598 .182 .361 .624 .654 .097 .749 .888 .785 .903 .076 .821 .414 
N 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 
Weight_Kg Correlation 
Coefficient 
-.571* .337 1.000 .728** .063 .008 -.053 .369 .059 .262 .159 -.181 -.094 -.034 -.471 -.395 -.566* -.483* .012 -.112 -.118 
Sig. (2-tailed) .017 .185 . .001 .810 .977 .841 .145 .823 .309 .541 .486 .720 .896 .057 .117 .018 .050 .963 .670 .653 
N 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 
BMI Correlation 
Coefficient 
-.556* -.300 .728** 1.000 .378 .187 .079 .712** .203 .056 .402 -.343 -.279 .316 -.667** -.542* -.681** -.664** -.392 -.185 -.306 
Sig. (2-tailed) .020 .241 .001 . .135 .471 .763 .001 .434 .830 .110 .178 .278 .216 .003 .025 .003 .004 .119 .477 .232 
N 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 
RecurrentFaller Correlation 
Coefficient 





Sig. (2-tailed) .629 .017 .810 .135 . .000 .001 .134 .718 .395 .270 .395 .065 .103 .546 .630 .546 .468 .810 .546 .329 
N 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 
Number of falls 
past 12 months 
Correlation 
Coefficient 
.274 -.364 .008 .187 .822** 1.000 .983** .246 .059 -.207 .369 -.277 -.587* .442 -.146 -.094 -.210 -.177 .020 -.236 -.248 
Sig. (2-tailed) .287 .150 .977 .471 .000 . .000 .342 .821 .425 .145 .281 .013 .076 .575 .718 .418 .497 .940 .361 .337 
N 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 
Faller Correlation 
Coefficient 
.330 -.291 -.053 .079 .717** .983** 1.000 .150 .000 -.211 .343 -.264 -.573* .422 -.079 -.026 -.158 -.105 .053 -.224 -.211 
Sig. (2-tailed) .196 .257 .841 .763 .001 .000 . .566 1.000 .417 .178 .307 .016 .092 .763 .920 .544 .687 .841 .387 .417 
N 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 
FOF Correlation 
Coefficient 
-.264 -.371 .369 .712** .378 .246 .150 1.000 .580* .316 .738** -.580* -.519* .659** -.738** -.501* -.632** -.685** -.474 -.620** -.738** 
Sig. (2-tailed) .306 .143 .145 .001 .134 .342 .566 . .015 .216 .001 .015 .033 .004 .001 .041 .006 .002 .054 .008 .001 





-.178 -.138 .059 .203 .094 .059 .000 .580* 1.000 .456 .547* -.240 -.363 .409 -.574* -.529* -.583* -.642** -.525* -.447 -.429 
Sig. (2-tailed) .494 .598 .823 .434 .718 .821 1.000 .015 . .066 .023 .353 .152 .103 .016 .029 .014 .005 .031 .072 .086 
N 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 
STS_Best Correlation 
Coefficient 
-.038 .340 .262 .056 -.220 -.207 -.211 .316 .456 1.000 .355 -.451 -.447 .397 -.333 -.431 -.471 -.400 -.225 -.539* -.424 
Sig. (2-tailed) .885 .182 .309 .830 .395 .425 .417 .216 .066 . .162 .069 .072 .115 .191 .084 .057 .112 .384 .026 .090 
N 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 
RST_Best Correlation 
Coefficient 
-.192 -.236 .159 .402 .283 .369 .343 .738** .547* .355 1.000 -.757** -.678** .775** -.657** -.566* -.603* -.674** -.512* -.896** -.909** 
Sig. (2-tailed) .461 .361 .541 .110 .270 .145 .178 .001 .023 .162 . .000 .003 .000 .004 .018 .010 .003 .036 .000 .000 





-.056 .128 -.181 -.343 -.220 -.277 -.264 -.580* -.240 -.451 -.757** 1.000 .805** -.846** .618** .498* .485* .569* .510* .667** .779** 





N 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 
SLST_Best Correlation 
Coefficient 
-.295 .117 -.094 -.279 -.457 -.587* -.573* -.519* -.363 -.447 -.678** .805** 1.000 -.775** .533* .569* .632** .610** .404 .587* .617** 
Sig. (2-tailed) .250 .654 .720 .278 .065 .013 .016 .033 .152 .072 .003 .000 . .000 .027 .017 .006 .009 .108 .013 .008 
N 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 
FSST_Best Correlation 
Coefficient 
.095 -.416 -.034 .316 .409 .442 .422 .659** .409 .397 .775** -.846** -.775** 1.000 -.600* -.424 -.449 -.534* -.627** -.645** -.733** 
Sig. (2-tailed) .718 .097 .896 .216 .103 .076 .092 .004 .103 .115 .000 .000 .000 . .011 .090 .071 .027 .007 .005 .001 





.376 .084 -.471 -.667** -.157 -.146 -.079 -.738** -.574* -.333 -.657** .618** .533* -.600* 1.000 .843** .809** .941** .630** .396 .507* 
Sig. (2-tailed) .137 .749 .057 .003 .546 .575 .763 .001 .016 .191 .004 .008 .027 .011 . .000 .000 .000 .007 .115 .038 





.298 -.037 -.395 -.542* -.126 -.094 -.026 -.501* -.529* -.431 -.566* .498* .569* -.424 .843** 1.000 .875** .941** .605* .351 .370 
Sig. (2-tailed) .245 .888 .117 .025 .630 .718 .920 .041 .029 .084 .018 .042 .017 .090 .000 . .000 .000 .010 .167 .144 





.320 -.071 -.566* -.681** -.157 -.210 -.158 -.632** -.583* -.471 -.603* .485* .632** -.449 .809** .875** 1.000 .936** .525* .406 .382 
Sig. (2-tailed) .210 .785 .018 .003 .546 .418 .544 .006 .014 .057 .010 .048 .006 .071 .000 .000 . .000 .031 .106 .130 





.376 .032 -.483* -.664** -.189 -.177 -.105 -.685** -.642** -.400 -.674** .569* .610** -.534* .941** .941** .936** 1.000 .635** .423 .468 
Sig. (2-tailed) .137 .903 .050 .004 .468 .497 .687 .002 .005 .112 .003 .017 .009 .027 .000 .000 .000 . .006 .090 .058 





.221 .441 .012 -.392 -.063 .020 .053 -.474 -.525* -.225 -.512* .510* .404 -.627** .630** .605* .525* .635** 1.000 .245 .358 
Sig. (2-tailed) .394 .076 .963 .119 .810 .940 .841 .054 .031 .384 .036 .037 .108 .007 .007 .010 .031 .006 . .342 .158 







.077 .059 -.112 -.185 -.158 -.236 -.224 -.620** -.447 -.539* -.896** .667** .587* -.645** .396 .351 .406 .423 .245 1.000 .945** 
Sig. (2-tailed) .768 .821 .670 .477 .546 .361 .387 .008 .072 .026 .000 .003 .013 .005 .115 .167 .106 .090 .342 . .000 
N 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 
Best_FGS Correlation 
Coefficient 
.052 .212 -.118 -.306 -.252 -.248 -.211 -.738** -.429 -.424 -.909** .779** .617** -.733** .507* .370 .382 .468 .358 .945** 1.000 
Sig. (2-tailed) .844 .414 .653 .232 .329 .337 .417 .001 .086 .090 .000 .000 .008 .001 .038 .144 .130 .058 .158 .000 . 
N 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 17 
 
